HDL biology 1016 items
Reverse cholesterol transport, efflux capacity and the hypothesis that started it all.
Trials, agents, guidance
- Guideline Where the HDL hypothesis stands after the CETP trials
- Agent Evacetrapib
- Agent Dalcetrapib
- Trial ACCELERATE
- Trial dal-OUTCOMES
Studies
- Landmark study links large HDL and LDL particle size and the CETP 405 valine allele to exceptional human longevity (JAMA 2003)
- The original discovery that hamster CETP uniquely drives one-way lipid flow from VLDL to HDL reveals CETP orthologs are not functionally equivalent across species (J Lipid Res 2014)
- Landmark JAMA meta-analysis of over 190,000 people finds CETP genotypes that inhibit CETP activity only weakly reduce coronary risk (JAMA 2008)
- CETP expression multiplies atherosclerotic lesion area 7-fold in the new E3L.CETP mouse model (Arterioscler Thromb Vasc Biol 2006)
- HDL from CETP-deficient people shows 2- to 3-fold greater cholesterol efflux from macrophages via an ABCG1-dependent pathway enriched in LCAT and apoE (J Clin Invest 2006)
- The Hugh Sinclair Lecture synthesizes how ABCA1, LCAT, CETP, hepatic lipase, and PLTP together remodel HDL, naming CETP inhibition as a resulting therapeutic strategy (Atheroscler Suppl 2002)
- A CETP-targeting vaccine cuts plasma CETP activity, raises HDL by 42%, and shrinks aortic lesions 39.6% in rabbits (Arterioscler Thromb Vasc Biol 2000)
- Duff Memorial Lecture synthesizes how CETP and PLTP knockouts revealed the liver pathways governing HDL catabolism (Arterioscler Thromb Vasc Biol 2000)
- CETP and Cyp7a share an LXR-controlled sterol response, coordinating hepatic cholesterol ester catabolism with bile acid synthesis (J Clin Invest 2000)
- CETP expression cuts aortic lesion area 41% and restores HDL cholesteryl ester clearance in LCAT-transgenic mice with dysfunctional HDL (J Biol Chem 1999)
- LTIP, not CETP itself, explains why cholesteryl ester transfer favors HDL over LDL, overturning a long-held assumption (Arterioscler Thromb Vasc Biol 1999)
- Annual Review synthesizes CETP structure, the reverse cholesterol transport hypothesis, and the SREBP-driven regulation of the CETP gene (Annu Rev Nutr 1998)
- An antibody blocking CETP-mediated lipid transfer sharply cuts HDL cholesteryl ester uptake by human adipocytes, revealing a direct CETP-dependent route into fat cells (J Biol Chem 1997)
- CETP incubation shrinks reconstituted HDL from 9.4 to 7.8 nm while raising particle count 50%, the first direct evidence of CETP-driven particle fusion (J Biol Chem 1997)
- Purified recombinant CETP acts as a lipid carrier with Km of 700 nM for LDL and 2000 nM for HDL, establishing its core kinetic mechanism (Biochem J 1996)
- Landmark Honolulu Heart Program study first shows CETP gene mutations raise coronary heart disease risk despite raising HDL cholesterol (J Clin Invest 1996)
- Exon-9-deleted CETP mRNA yields an inactive protein, while hypercholesterolemia and development favor full-length transcript accumulation (J Biol Chem 1996)
- In mice, whether CETP protects against or promotes atherosclerosis depends entirely on triglyceride status, protective only when hypertriglyceridemic (J Clin Invest 1995)
- Two independent inhibitors reveal separate CETP binding sites for cholesteryl ester and triglyceride transfer, uncoupled in vivo (J Biol Chem 1995)
- Landmark ECTIM study is the first to show alcohol intake determines whether the CETP B2 allele protects against heart attack (J Clin Invest 1995)
- K233 and R259 are essential CETP residues for lipoprotein binding, conserved across the CETP/PLTP/LPS-binding-protein gene family (Biochemistry 1995)
- CETP binds preferentially to the edge of nascent discoidal HDL particles, with affinity boosted 3- to 10-fold by cholesteryl ester or cholesterol content (J Biol Chem 1995)
- A comprehensive Annual Review of Biochemistry synthesis by Alan Tall concludes CETP is dominantly antiatherogenic in vivo despite lowering HDL cholesterol (Annu Rev Biochem 1995)
- CETP deficiency from two prevalent mutations is identified as the first common genetic cause of high HDL cholesterol in the general population (J Clin Invest 1994)
- CETP enriches HDL with triglyceride, accelerating lipolysis-driven apoA-I shedding and shortening apoA-I half-life, explaining low HDL in CETP mice (J Biol Chem 1994)
- The original discovery of CETP mutation D442G reveals a dominant-negative multimeric mechanism causing threefold HDL elevation in heterozygotes (J Clin Invest 1993)
- CETP shrinks HDL from 10.3 to 7.6 nm and increases apoA-I catabolic rate 35% in hypertriglyceridemic transgenic mice, revealing the kinetic basis of low HDL (J Clin Invest 1993)
- CETP crossed with human apoA-I transgenic mice deepens HDL cholesterol loss to 66%, revealing an enhanced human-CETP/human-apoA-I interaction (J Clin Invest 1992)
- A 50% rise in CETP activity after probucol tracks plasma drug levels and inversely predicts the fall in HDL cholesterol (Eur J Clin Invest 1991)
- Linker-insertion mutagenesis maps three CETP regions essential for lipid transfer, at residues 48-53, 165, and 373-379 (Biochemistry 1991)
- A common CETP gene splicing mutation causes markedly elevated HDL in Japan without excess atherosclerosis (N Engl J Med 1990)
- An anti-CETP antibody fully blocks CETP-driven HDL3 size conversion, proving CETP drives structural remodeling beyond lipid transfer (J Lipid Res 1990)
- The original discovery of the intron 14 splice-site mutation identifies the molecular cause of CETP deficiency in four Japanese families (Biochem Biophys Res Commun 1990)
- Two Japanese siblings with markedly increased HDL are found homozygous for a CETP intron-14 splice-site mutation eliminating the protein (Nature 1989)
- A neutralizing anti-CETP antibody eliminates all neutral lipid mass transfer in human plasma, while HDL serves as the main early LCAT substrate (J Clin Invest 1989)
- CETP boosts HDL cholesteryl ester uptake into HepG2 liver cells 2.8-fold, the original demonstration of CETP-facilitated selective cellular cholesterol delivery (J Biol Chem 1987)
- Human but not rat lipoprotein-deficient serum drives cholesteryl ester efflux from cultured arterial smooth muscle cells, implicating CETP in interstitial cholesterol removal (Biochim Biophys Acta 1985)
- Without CETP, LCAT activity stalls once cholesteryl ester reaches a 0.03 ester-to-lecithin ratio; CETP clears the product to sphingomyelin liposomes to keep LCAT running (Biochemistry 1980)
- The Morton lab introduces substrate-preference modification as a new paradigm for engineering CETP-targeting drugs (J Lipid Res 2015)
- A landmark review proposes the first comprehensive step-by-step molecular model of CETP action: sensing, penetration, docking, ternary complex, transfer, dissociation (J Lipid Res 2012)
- Molecular dynamics simulations reveal helix X of CETP as a lid gating lipid exchange with HDL (PLoS Comput Biol 2012)
- Large Copenhagen study shows CETP-mutation-driven HDL elevation actually raises heart disease risk in women, not lowers it (Circulation 2000)
- TULIP: the original TA-8995 (obicetrapib) trial cuts LDL-C by up to 45.3% and raises HDL-C by up to 179% with no serious adverse events (Lancet 2015)
- 13,677-subject meta-analysis confirms CETP TaqIB drives HDL and CAD risk but does not affect pravastatin response (Circulation 2005)
- CETP protein-truncating variants cut coronary artery disease risk even in Japanese patients with severe familial hypercholesterolemia (Atherosclerosis 2025)
- CETP expression preserves endothelial function in female mice via enhanced estrogen receptor-alpha and eNOS signaling, unlike its harmful effect in males (Am J Physiol Heart Circ Physiol 2023)
- Why raising HDL with CETP inhibitors did not help: evacetrapib and torcetrapib both boosted the harmful apoC3-containing HDL subspecies most (Arterioscler Thromb Vasc Biol 2022)
- HDL-cholesterol predicts carotid atherosclerosis only when CETP concentration is low, in the IMPROVE study (Biomedicines 2021)
- Swapping hamster CETP for human CETP cuts HDL by 60% and boosts hepatic cholesterol 1.8-fold in a human-like hamster model (J Lipid Res 2021)
- Elevated CETP activity during acute STEMI independently predicts endothelial dysfunction and 12.8-fold higher 30-day mortality risk (Atherosclerosis 2014)
- Genome-wide analysis of 18,245 women finds CETP is the only HDL-raising locus that also lowers heart attack risk, supporting a causal role (Circ Cardiovasc Genet 2009)
- CETP discovered to protect mice against lethal bacterial endotoxin by dampening the inflammatory response (Shock 2008)
- Niacin raises HDL cholesterol by suppressing hepatic CETP expression, not by any CETP-independent route (Arterioscler Thromb Vasc Biol 2008)
- CETP coding variants R451Q and A373P predict coronary calcium independent of HDL cholesterol in a multi-ethnic cohort (Atherosclerosis 2008)
- Genome-wide meta-analysis of 20,000-plus people confirms CETP among eleven established lipid loci and finds new ones (Nat Genet 2008)
- CETP expression boosts macrophage reverse cholesterol transport in mice via the LDL receptor pathway (Circulation 2007)
- Fenofibrate raises HDL cholesterol by up to 91% only in the presence of CETP, via a 72% reduction in hepatic CETP expression, in transgenic mice (J Lipid Res 2007)
- A CETP variant that raises HDL cholesterol paradoxically raises coronary risk once HDL-cholesterol is accounted for, large PREVEND study finds (J Clin Endocrinol Metab 2006)
- The EPIC-Norfolk study finds elevated CETP predicts higher future coronary artery disease risk, but only in people with high triglycerides (Circulation 2004)
- High baseline CETP predicts worse atherosclerosis progression on statins in familial hypercholesterolemia (Atherosclerosis 2004)
- Plasma CETP concentration, not TaqIB genotype, predicts atherosclerosis progression and pravastatin benefit in REGRESS (Eur J Clin Invest 2004)
- CETP transgene expression reverses the cholesterol-raising effect of LXR agonists and instead lowers hepatic cholesterol while boosting biliary excretion in mice (J Lipid Res 2004)
- Combined CETP gene polymorphisms explain up to 10 percent of the variation in carotid intima-media thickness (Eur J Clin Invest 2001)
- ApoC-I identified as the natural CETP inhibitor carried on HDL (J Biol Chem 2000)
- CETP mutations that lower HDL cholesterol paradoxically cut ischemic heart disease risk 36% in women, Copenhagen City Heart Study finds (Circulation 2000)
- Combining a CETP transgene with PLTP deficiency additively lowers HDL cholesteryl ester and apoA-I in mice, showing no functional redundancy (J Biol Chem 2000)
- CETP TaqIB B2 allele lowers CHD risk in men in the Framingham Offspring Study (Arterioscler Thromb Vasc Biol 2000)
- CETP remodeling of HDL boosts SR-BI-mediated cholesteryl ester uptake 2- to 4-fold, synergizing with hepatic lipase in reverse cholesterol transport (J Lipid Res 1999)
- Vitamin E blocks the CETP-lowering effect of pravastatin and raises CETP concentration on its own (Coron Artery Dis 1998)
- Oleate suppresses LTIP activity over 80%, unleashing maximal CETP-mediated lipid transfer between all lipoproteins including LDL (Arterioscler Thromb Vasc Biol 1997)
- CETP activity correlates with LDL-cholesterol but not HDL-cholesterol in 586 healthy Japanese adults (Atherosclerosis 1996)
- ARP-1 acts as both repressor and activator of the CETP gene promoter depending on flanking sequence context, via a defined 105-bp regulatory element (J Biol Chem 1995)
- Deleting six carboxyl-terminal residues of CETP abolishes cholesteryl ester and triglyceride binding without affecting HDL association (J Biol Chem 1995)
- Stable-isotope kinetics show CETP deficiency raises HDL by slowing apoA-I and apoA-II catabolism, not by increasing production (J Clin Invest 1993)
- CETP is locally synthesized and secreted within the human brain, not just imported from plasma (Int J Clin Lab Res 1992)
- CETP deficiency dose-dependently raises HDL2 cholesterol up to sixfold in homozygotes and twofold in heterozygotes (Metabolism 1991)
- Plasma CETP rises up to 85 percent in dysbetalipoproteinemia and severe chylomicronemia, correcting with dietary treatment (Arterioscler Thromb 1991)
- CETP has dedicated binding sites for cholesteryl ester, triglyceride, and phospholipid that let it ferry lipids between particles (J Biol Chem 1988)
- Lipolysis products bind CETP directly to VLDL remnants and HDL, driving faster cholesteryl ester transfer (J Biol Chem 1985)
- Lipoprotein lipase and CETP together boost cholesteryl ester transfer 2 to 8 fold beyond CETP alone (J Biol Chem 1984)
- CETP activity, but not mass, is independently linked to coronary disease in patients with high HDL cholesterol (Anatol J Cardiol 2026)
- Post hoc BROADWAY/BROOKLYN analysis: obicetrapib attenuates kidney function decline, tracking with achieved HDL-C (Am J Prev Cardiol 2026)
- Network meta-analysis of 2,937 patients: obicetrapib outperforms anacetrapib on LDL-C, HDL-C and overall adverse events (Daru 2026)
- GRADE-assessed meta-analysis of 3,399 patients: obicetrapib raises the odds of reaching an LDL-C target under 55 mg/dL more than sixfold (Diabetes Obes Metab 2026)
- A mathematical model extends CETP-mediated triglyceride flux estimation to chylomicrons in postprandial lipemia (J Lipid Res 2025)
- CETP expression abolishes the atheroprotective effect of large HDL particles in mouse models of type 1 diabetes (Circ Res 2024)
- A Polynesian-specific CETP missense variant lowers CETP activity by 27.9% and improves the lipid profile (HGG Adv 2023)
- CETP expression in macrophages curbs mitochondrial oxidant production and dampens pro-inflammatory, cholesterol-laden phenotypes (Antioxidants 2022)
- Abdominal aortic aneurysm patients show 49% higher CETP activity and altered HDL cholesterol efflux compared with atherosclerosis controls (Front Immunol 2022)
- Hibernating brown bears raise CETP activity by 36% to stabilize HDL lipid composition and avoid atherogenic dyslipidemia (Sci Rep 2021)
- Advanced mass spectrometry reveals that CETP is secreted in medium-large HDL and stays there, unlike LCAT which appears on HDL only after a delay (JCI Insight 2021)
- A human CETP minigene improves insulin sensitivity and reduces fatty liver in female but not male mice on a high-fat diet (Front Physiol 2021)
- Swapping hamster CETP for human CETP in chow-fed hamsters humanizes their lipoprotein profile, cutting HDL up to 50% (J Lipid Res 2020)
- Elevated CETP activity in early pregnancy predicts prediabetes five years later, tracking with monocyte activation (J Clin Endocrinol Metab 2020)
- Genetic CETP inhibition doesn't touch particle-size-defined LDL-C the way statins do, but lowers remnant, VLDL and HDL-triglyceride content instead (PLoS Biol 2019)
- ApoF knockdown boosts CETP-mediated cholesterol ester transfer to LDL and impairs cholesterol clearance in fat-fed hamsters (J Lipid Res 2019)
- Evacetrapib raises large and medium HDL but cuts the functionally important preβ-1 HDL by 36%, a clue to why raising HDL-C didn't help (Atherosclerosis 2019)
- Mendelian randomisation upends the textbook story: the causal effects of CETP fall mainly on large HDL and small VLDL, not LDL, hinting anacetrapib works by cutting VLDL (Eur J Hum Genet 2019)
- CETP-deficient patients show markedly more large HDL particles but fewer small, more anti-atherogenic HDL particles, alongside more atherogenic very small LDL (PLoS One 2018)
- Weight loss plus exercise normalizes the HDL lipidome, lowers CETP activity, and boosts cholesterol efflux capacity in metabolic syndrome (Arterioscler Thromb Vasc Biol 2018)
- Glucocorticoids downregulate CETP gene expression in macrophages, and doubling hydrocortisone dose lowers CETP activity and raises HDL size in patients (Eur J Clin Invest 2017)
- CETP redistributes the vasoprotective lipid sphingosine-1-phosphate from HDL to apoB lipoproteins, changing which signals it triggers (Arterioscler Thromb Vasc Biol 2017)
- Arsenic trioxide independently raises CETP protein levels in liver cells while suppressing LXR-beta and cholesterol efflux (Chem Biol Interact 2016)
- The CETP locus is the only genome-wide-significant genetic determinant of HDL-C response to statins, independent of baseline HDL-C, in a 27,720-person meta-analysis (J Med Genet 2016)
- TA-8995 (obicetrapib) raises ABCA1-specific cholesterol efflux capacity by 28% and preBeta-1 HDL by 36%, showing functional as well as HDL-C gains (J Clin Lipidol 2016)
- Evacetrapib raises ABCA1-specific cholesterol efflux capacity and pre-beta-1 HDL, effects that statins alone do not share (JACC 2015)
- Topoisomerase II inhibitors etoposide and teniposide activate hepatic CETP expression via LXR and boost reverse cholesterol transport in CETP transgenic mice (J Biol Chem 2015)
- CETP -629C/A genotype predicts HDL-C but the CC genotype benefits most from atorvastatin's LDL-C-lowering effect in Chinese CHD patients (Med Sci Monit 2014)
- CETP genotype predicts who benefits most from a low-carbohydrate diet for raising HDL and lowering triglycerides, replicated across two randomized trials (J Lipid Res 2015)
- Mendelian randomization using the CETP TaqIB polymorphism finds genetically raised HDL cholesterol does not translate into lower coronary disease risk (BMC Med Genet 2014)
- Bone marrow-derived hepatic lipase mitigates the HDL-lowering effect of bone marrow-derived CETP in double-knockout mice (J Lipid Res 2014)
- CETP activity is 30 percent higher in South Asians than Europeans and tracks the full pattern of atherogenic dyslipidemia (Eur J Prev Cardiol 2014)
- The dal-ACUTE trial finds dalcetrapib raises HDL cholesterol by a third after acute coronary syndrome but boosts cholesterol efflux by only a tenth (Eur Heart J 2014)
- Fibrates and fish oil, but not corn oil, activate PPAR-alpha to raise hepatic CETP expression and plasma activity in transgenic mice (J Nutr Biochem 2014)
- CETP enhancer variant rs3764261 boosts statin-associated HDL-C rise but reduces statin protection against myocardial infarction (Clin Pharmacol Ther 2013)
- Cysteine 13 of CETP is the key residue that lets dalcetrapib decouple cholesteryl ester transfer from HDL remodeling (Biochim Biophys Acta 2013)
- Bile-acid-activated farnesoid X receptor identified as a novel driver of CETP expression, explaining low HDL-C in cholestasis (J Lipid Res 2013)
- HIV/HAART patients show a blunted triglyceride-HDL cholesterol relationship driven by higher CETP mass but lower CETP-specific activity, not altered total CETP activity (Metabolism 2013)
- In the Framingham Heart Study, low CETP or high PLTP activity predicts more than double the cardiovascular risk in men but not women (Atherosclerosis 2013)
- CETP R451Q raises coronary stenosis risk while Taq1B B2 lowers it in a Tunisian angiography cohort (J Cardiovasc Med (Hagerstown) 2012)
- CETP and ABCA1 genotype together determine whether atorvastatin or simvastatin gives a better lipid response (Angiology 2012)
- Heterozygous CETP-deficient HDL is remodeled toward more cholesteryl ester and less triglyceride but keeps normal antioxidative capacity (PLoS One 2012)
- CETP deficiency, not high CETP activity, impairs postprandial lipemia clearance and correlates with carotid atherosclerosis in women (Lipids Health Dis 2011)
- CETP protects against the rise in VLDL caused by reconstituted HDL infusion, resolving a mouse-versus-human discrepancy (J Lipid Res 2011)
- Plasma cholesteryl ester transfer activity, not CETP mass, predicts incident cardiovascular disease in a nested case-control study (Atherosclerosis 2011)
- CETP variant rs1532624 reduces heart attack risk in women regardless of physical activity level, unlike an LPL variant with an activity-dependent effect (Circ Cardiovasc Genet 2011)
- CETP activity is higher in obese adolescent boys and correlates with more TV watching and higher milk intake (Arch Med Res 2011)
- CETP TaqI and -629C/A variants predict a bigger HDL-C rise on atorvastatin, while CETP 405I/V predicts higher MI risk in CAD patients (DNA Cell Biol 2010)
- Higher on-statin CETP mass predicts fewer recurrent coronary events in the PROVE IT-TIMI 22 trial (Am J Cardiol 2010)
- Anacetrapib doubles HDL cholesterol and, unlike niacin, boosts cholesterol efflux per particle at high HDL levels (ATVB 2010)
- CETP restores HDL cholesterol in SR-BI-deficient mice but fails to prevent atherosclerosis (Arterioscler Thromb Vasc Biol 2010)
- LXRalpha, not LXRbeta, drives human CETP transcription, confirmed in monkeys, human-CETP-transgenic mice, and HepG2 cells (Atherosclerosis 2010)
- Falling CETP levels during hospitalization predict mortality in patients with severe sepsis (Eur J Clin Invest 2010)
- Pioglitazone lowers plasma CETP mass and hepatic triglyceride content while raising HDL cholesterol in type 2 diabetes, confirming prior mouse findings (Diabetes Care 2010)
- CETP raises HDL triglyceride but leaves triglyceride production and clearance unchanged in APOE*3-Leiden mice (J Lipid Res 2010)
- High fasting CETP levels predict a larger postprandial HDL cholesterol drop after fat-rich meals, independent of triglyceride rise, in the Hoorn prandial study (Metabolism 2010)
- Higher circulating CETP activity predicts fewer cardiovascular events over 15 years in the Framingham Heart Study (Circulation 2009)
- Ciprofibrate boosts CETP gene expression and speeds cholesterol delivery to the liver in CETP-transgenic mice (Lipids Health Dis 2009)
- Berry anthocyanins raise HDL and lower LDL cholesterol via natural CETP inhibition in a placebo-controlled trial (Am J Clin Nutr 2009)
- Higher CETP quartiles predict more coronary calcium and thicker carotid intima-media in Japanese men, independent of D442G genotype (Am J Cardiol 2009)
- CETP gene mutations shape LDL and HDL cholesterol from birth through the first year of life (Clin Chim Acta 2009)
- CETP delays clearance of dietary fat by slowing triglyceride clearance and suppressing lipoprotein lipase (Biochem J 2009)
- CETP TaqIB B2 allele linked to higher HDL cholesterol in Greek children (Nutr Metab Cardiovasc Dis 2010)
- CETP drives atherosclerosis mainly by raising VLDL-cholesterol, not by lowering HDL-cholesterol, in APOE*3-Leiden mice (Atherosclerosis 2009)
- Tesaglitazar lowers CETP mass and activity and halts progression of existing atherosclerosis in CETP-transgenic mice (Br J Pharmacol 2009)
- A novel CETP R37X mutation causes complete CETP deficiency and extreme HDL elevation without atherosclerosis in a Swedish man (Atherosclerosis 2009)
- Rising VLDL-triglyceride from bexarotene drives CETP activity up and HDL cholesterol down (Endocrinology 2009)
- CETP variants without known cardioprotective effects still raise large HDL particle concentrations by up to 40 percent, questioning what HDL particle size means (Clin Chem 2009)
- CETP expression reverses the direction of PXR agonism effect on HDL cholesterol, turning an increase in mice into a dose-dependent decrease (Biochim Biophys Acta 2009)
- The combined action of SAA, secretory phospholipase A2, and CETP remodels HDL during the acute phase response while preserving cholesterol efflux capacity (Arterioscler Thromb Vasc Biol 2009)
- Acute coronary syndrome reduces leucocyte CETP expression up to 6-fold, with recovery tracking reduced inflammation, confirmed in CETP transgenic mice (J Intern Med 2008)
- Apple polyphenols improve cholesterol distribution in hamsters by directly inhibiting CETP activity (Mol Nutr Food Res 2008)
- FXRalpha suppresses CETP gene expression by competing with LXRalpha at a shared promoter element (Mol Cells 2008)
- CETP Taq1B B2 variant cuts metabolic syndrome risk by up to 57% in a large Austrian cohort (Obesity (Silver Spring) 2008)
- Combined CETP- and hepatic-lipase-lowering gene variants raise HDL cholesterol but still increase coronary disease risk in the REGRESS trial (Atherosclerosis 2008)
- CETP plasma levels are positively correlated with blood clotting speed, and recombinant CETP enhances prothrombinase activity, revealing a previously unknown procoagulant role (Thromb Haemost 2007)
- Complexing with spherical HDL protects CETP from mast cell chymase degradation, while CETP reciprocally protects discoidal HDL (J Lipid Res 2008)
- Atorvastatin's HDL-raising effect in mice requires CETP expression, proving statins work partly by suppressing CETP (Atherosclerosis 2007)
- Pioglitazone and rosiglitazone move CETP activity in opposite directions despite similar glucose control (Diabetes Metab Res Rev 2007)
- Hepatic lipase and CETP gene variants interact to raise HDL-C, but the combined genotype does not lower cardiovascular risk (J Clin Endocrinol Metab 2007)
- Higher plasma CETP predicts lower cardiovascular event risk specifically in men with low triglycerides, in the PREVEND study (Eur Heart J 2007)
- Bone marrow-derived CETP alone drives a proatherogenic lipid profile and 1.8-fold more atherosclerosis, and Kupffer cells supply half of hepatic CETP, in LDL receptor knockout mice (Circ Res 2007)
- CETP haplotype linked to higher HDL-C across three populations shows no association with coronary heart disease risk (Hum Genet 2007)
- CETP expression protects SR-BI-deficient mice from diet-induced atherosclerosis by remodeling buoyant HDL toward normal density (Arterioscler Thromb Vasc Biol 2007)
- A rare long CETP allele raises coronary artery disease risk nearly 7-fold in Corsican patients (Exp Mol Pathol 2006)
- A rapid 6-hour HDL subfractionation method reveals HDL has a dual role in oxidation: CETP-dependent prooxidant during VLDL oxidation, antioxidant during LDL oxidation (J Lipid Res 2007)
- CETP directly delivers HDL cholesteryl ester to the liver independent of SR-BI and LDL receptor pathways (Biochim Biophys Acta 2006)
- A DNA vaccine displaying a CETP epitope on hepatitis B core protein cuts aortic lesion area by 80.6% in a rabbit atherosclerosis model (Vaccine 2006)
- CETP expression cuts atherosclerotic lesion size 44% in testosterone-deficient mice (J Lipid Res 2006)
- CETP TaqIB rare allele is linked to lower internal carotid artery thickness in men, in the Framingham Heart Study (Atherosclerosis 2006)
- CETP inhibition in rabbits blocks one HDL cholesteryl ester removal pathway but does not compromise overall clearance from plasma (Arterioscler Thromb Vasc Biol 2005)
- A high-fat monounsaturated diet blocks cholesterol from stimulating CETP by suppressing LXR-alpha expression, unlike a low-fat diet (J Lipid Res 2005)
- CETP TaqI B1/B2 genotype differs significantly in men with venous thrombosis, tracking their low-HDL/high-LDL profile (Circulation 2005)
- A CETP-epitope vaccine carried by heat shock protein-65 reduces aortic lesions by up to 30.8% in rabbits (J Cardiovasc Pharmacol 2005)
- CETP Taq1B genotype predicts who benefits from cardiac rehabilitation's lipid effects (Atherosclerosis 2005)
- CETP variants linked to HDL cholesterol are not the same ones linked to heart attack history, resolving a literature contradiction (Atherosclerosis 2005)
- ApoCI overexpression backfires as a CETP-blocking strategy by triggering compensatory CETP gene induction (Biochem J 2005)
- Rosuvastatin cuts CETP mass 33-37% and, in hypertriglyceridemic patients, transfer activity by 59% (Atherosclerosis 2003)
- Probucol still lowers HDL cholesterol in humans with complete CETP deficiency, disproving its CETP-dependent mechanism (Atherosclerosis 2003)
- Streptozotocin-induced diabetes raises CETP mass and activity in transgenic mice, partly reversed by insulin (Can J Physiol Pharmacol 2003)
- LTIP steers CETP's lipid-transfer preference toward HDL3 while keeping HDL2 activity low and constant (J Biol Chem 2003)
- Garlic supplementation lowers CETP activity and shrinks atherosclerotic lesions in cholesterol-fed rabbits (Life Sci 2003)
- Sp1 and Sp3 transcription factors regulate the human CETP gene promoter through three binding sites, with the Sp1/Sp3 ratio determining their relative activity (J Lipid Res 2003)
- Haplotype analysis reveals that the famous CETP TaqIB polymorphism is not actually a driver of CETP or HDL cholesterol levels (J Mol Med 2003)
- Meta-analysis of over 10,000 people confirms both CETP TaqIB and I405V variants significantly raise HDL cholesterol (J Lipid Res 2003)
- An Alu repeat represses and a CPF binding site activates the human CETP gene's distal promoter (J Lipid Res 2003)
- CETP expression halves aortic lesion area in ovariectomized mice, an atheroprotective effect blunted by estrogen therapy (J Lipid Res 2003)
- Expressing simian CETP in Fisher rats cuts HDL cholesterol by 48%, selectively depleting large apoE-containing HDL1 particles by 74% (J Lipid Res 2002)
- Meal-induced CETP activity redirects HDL cholesterol esters toward atherogenic VLDL-1 particles, rising 32-fold in type IIB hyperlipidemia versus healthy controls (J Lipid Res 2002)
- High plasma CETP does not speed reverse cholesterol transport in vivo despite raising liver cholesteryl ester uptake (Atherosclerosis 2002)
- Higher-dose atorvastatin cuts CETP-mediated cholesteryl ester transfer 30% while boosting cholesterol efflux in type IIB hyperlipidemia (Atherosclerosis 2002)
- CETP D442G mutation enlarges LDL particle size in coronary heart disease patients, suggesting an antiatherogenic role (Clin Chim Acta 2002)
- LCAT deficiency posttranscriptionally suppresses plasma CETP levels, likely via loss of HDL (Arterioscler Thromb Vasc Biol 2002)
- CETP B2B2 genotype raises HDL cholesterol and particle size specifically in women in the Columbia BioMarkers Study (Nutr Metab Cardiovasc Dis 2002)
- CETP TaqIB B2B2 genotype replicates its HDL cholesterol and coronary benefit in men with low HDL, VA-HIT trial finds (Arterioscler Thromb Vasc Biol 2002)
- CETP genotype shapes which HDL subfractions rise with endurance exercise training (Metabolism 2002)
- Serum CETP is roughly double in obese children and falls with weight-loss therapy (Obes Res 2002)
- CETP D442G mutation flips its effect in fetal blood, lowering cholesterol instead of raising HDL as it does in adults (Atherosclerosis 2002)
- PLTP, not CETP, drives generation of pre-beta HDL in transgenic mice, a 3-fold rise versus CETP-only or wild-type animals (Biochem J 2001)
- First prospective study finds insulin therapy raises CETP without atherogenic lipid changes (Ann N Y Acad Sci 2001)
- CETP-LDL associations are strongest with saturated fat, hinting at why it drives atherogenesis (J Lipid Res 2001)
- Higher CETP levels roughly halve vascular disease risk in hemodialysis patients with normal or high HDL cholesterol, odds ratio 0.31 (Am J Kidney Dis 2001)
- CETP TaqIB B2 allele produces a less atherogenic lipid profile and fewer clinical signs in familial hypercholesterolemia (Metabolism 2001)
- Small-for-gestational-age neonates have lower CETP mass but higher cholesteryl ester transfer, possibly explaining later CHD risk (Metabolism 2001)
- Bile-acid feeding represses hepatic CETP expression in male mice but induces it in female mice, revealing a sex-specific regulatory response tied to LRH-1 (J Biol Chem 2001)
- Four CETP-transgenic mouse strains show lipoprotein cholesterol shifting between HDL and LDL in an allelic dose-dependent manner across a 2.9 to 37.4 microg/ml CETP range (Biochem Biophys Res Commun 2001)
- Rising triglycerides redirect CETP-mediated cholesterol transfer from LDL toward VLDL1, fueling small dense LDL in type 2 diabetes (Arterioscler Thromb Vasc Biol 2001)
- LDL oxidation redirects CETP transfer backward, pulling cholesteryl ester out of LDL and into HDL instead (Clin Chim Acta 2001)
- Combining apoA-II and CETP transgenes triggers massive VLDL overproduction in mice (J Lipid Res 2001)
- Extra-large HDL particles unique to genetic CETP deficiency may mark reduced atherosclerosis risk (Clin Chim Acta 2000)
- Infants have naturally high CETP activity that is unaffected by thyroid hormone status, unlike prior reports (Metabolism 2000)
- Chronic growth hormone replacement lowers CETP activity alongside LCAT, improving the lipoprotein profile (J Lipid Res 2000)
- CETP TaqIB genotype raises HDL-cholesterol and lowers coronary disease only in men with type 2 diabetes (J Clin Endocrinol Metab 1999)
- An apoE-peptide carrier delivers antisense DNA into cell nuclei, cutting CETP mRNA over 50% and CETP activity to 53.8% of control in CHO cells (Arterioscler Thromb Vasc Biol 1999)
- CETP, unlike PLTP, rises with hyperlipidemia but stays flat in diabetes, a new ELISA study shows (Arterioscler Thromb Vasc Biol 1999)
- CETP and PLTP activity, not diabetes itself, drive elevated cholesteryl ester transfer in NIDDM (Atherosclerosis 1998)
- Beta-adrenergic stimulation drives CETP secretion from hamster adipose tissue through a cAMP pathway (Atherosclerosis 1998)
- Probucol raises CETP mRNA up to 221% and boosts cholesterol efflux 354% in a dose-dependent manner in CETP-transfected hamster ovary cells (Biochim Biophys Acta 1998)
- CETP preferentially transfers cholesteryl ester over triglyceride when interacting with HDL, independent of its HDL binding (J Biochem 1998)
- Expressing simian CETP in obese diabetic KKAy mice cuts HDL from 159 to 25 mg/dl by enriching HDL with triglyceride 10-fold (Am J Physiol 1998)
- Two hyperalphalipoproteinemia profiles show elevated, not deficient, CETP activity, with differing atherosclerosis risk (Atherosclerosis 1998)
- A bimodal CETP concentration pattern hints at hidden CETP mutations linked to I405V, raising heart disease risk in men with high triglycerides (J Lipid Res 1998)
- First Caucasian North American case of CETP deficiency traced to a novel exon 9 stop mutation (J Lipid Res 1998)
- Nearly 50,000-subject Japanese study finds no excess coronary heart disease in CETP-deficient people with very high HDL cholesterol (Prev Med 1998)
- Plasma CETP activity rises in hyperthyroidism and falls in hypothyroidism, correcting with treatment (J Clin Endocrinol Metab 1998)
- Lipoprotein-bound free fatty acids drive elevated CETP specific activity in nephrotic syndrome (Arterioscler Thromb Vasc Biol 1997)
- Human apoA-I transgenic mouse HDL lacks the heat-labile inhibitor that normally caps CETP activity at high HDL levels (J Biol Chem 1997)
- CETP deficiency raises HDL-C in familial hypercholesterolemia but fails to prevent coronary disease (Atherosclerosis 1997)
- CETP activity enhances plasma cholesteryl ester formation, confirmed in transgenic mice, hamsters, and humans with genetic CETP deficiency (Arterioscler Thromb Vasc Biol 1997)
- Growth hormone excess raises CETP activity and shifts LDL toward the small dense subfraction in acromegaly (Atherosclerosis 1997)
- CGS 25159, a synthetic isoflavan CETP inhibitor, cuts VLDL+LDL cholesterol 28% and raises HDL cholesterol 29% in hamsters (Atherosclerosis 1997)
- CETP accounts for 15.2% of HDL cholesterol variation in hypertriglyceridemic men, more than LCAT, lipases, or triglycerides individually (Arterioscler Thromb Vasc Biol 1997)
- CETP predicts low HDL cholesterol independent of lipoprotein lipase in hypertriglyceridemic men but not in normotriglyceridemic men (Arterioscler Thromb Vasc Biol 1996)
- LpA-I:A-II is an efficient CE donor to triglyceride-rich lipoproteins despite low CETP affinity, fenofibrate raising HDL cholesterol 28% without changing CETP mass (Arterioscler Thromb Vasc Biol 1996)
- Novel CETP nonsense mutation G181X found in 5 of 294 Japanese hyperalphalipoproteinemic subjects (J Lipid Res 1996)
- 13-cis-retinoic acid strongly activates CETP through its negatively charged carboxylic group (Eur J Biochem 1996)
- Lipoprotein lipase deficiency cuts cholesteryl ester transfer despite normal CETP mass, restored by adding lipoprotein lipase (J Lipid Res 1996)
- HDL3 electronegative charge density, peaking near minus 2,200 esu per square centimeter, governs maximal CETP activity (Biochim Biophys Acta 1996)
- Adding CETP to apoA-I transgenic mice doubles prebeta-HDL apoA-I and raises cholesterol efflux and LCAT esterification 1.7-fold (J Lipid Res 1996)
- Endotoxin cuts CETP levels below 20 percent of normal in hamsters, partly via TNF and interleukin-1 (J Clin Invest 1996)
- Analbuminemic patients show elevated CETP activity toward LDL, likely driven by lipoprotein-bound free fatty acids (Arterioscler Thromb Vasc Biol 1996)
- CETP activity, not mass, is elevated in Type 2 diabetes and tracks free cholesterol and apoA-I only in non-diabetic subjects (Atherosclerosis 1996)
- HDL particles from CETP-transgenic mice are more efficient cholesterol acceptors than from apoA-I-only transgenic mice, despite lower HDL levels (J Clin Invest 1995)
- CETP-mediated cholesteryl ester and triglyceride transfer in plasma is not an equimolar exchange (J Lipid Res 1995)
- Two novel compounds inhibit CETP by distinct mechanisms: U-95,594 competitively blocks all lipid transfer, U-617 selectively and irreversibly blocks CE transfer (Biochemistry 1995)
- CETP shuttles oxidized cholesteryl linoleate between LDL and HDL without distinguishing it from the unoxidized form (J Lipid Res 1995)
- The ratio of CETP mass to HDL3 cholesterol predicts carotid wall thickness better than HDL cholesterol itself (J Mol Med 1995)
- A high trans fatty acid diet raises serum CETP activity compared with linoleic or stearic acid diets (Atherosclerosis 1995)
- CETP activity splits into two distinct subgroups among low-HDL men, with the high-CETP subgroup showing only 30% coronary disease prevalence versus 70% (Arterioscler Thromb Vasc Biol 1995)
- CETP activity is 42 percent higher in hypercholesterolemia and correlates strongly with LDL cholesterol (Arterioscler Thromb Vasc Biol 1995)
- A monoclonal antibody against CETP raises hamster HDL cholesterol 33% and cuts HDL triglyceride 42% in vivo (Atherosclerosis 1994)
- Elevated CETP activity, correlated with low HDL, may explain reduced HDL cholesterol in obesity (Arterioscler Thromb 1994)
- A marker linked to the CETP locus shows significant linkage to plasma HDL-cholesterol levels in coronary disease families (Hum Genet 1994)
- PTP boosts the cholesteryl ester transfer activity of CETP even though the two proteins move phospholipids by distinct mechanisms (J Lipid Res 1994)
- CETP TaqIB B2B2 genotype raises HDL2 by 45 percent independent of CETP exchange activity itself (Arterioscler Thromb 1994)
- Trans-elaidic acid raises CETP activity more than cis-oleic acid, correlating with falling HDL cholesterol (Atherosclerosis 1994)
- Nine to twelve months of exercise training lowers plasma CETP concentration by about 14 percent (Arterioscler Thromb 1993)
- Elevated LCAT and CETP activities help explain abnormal HDL composition in nephrotic-range proteinuria (Kidney Int 1993)
- ApoE genotype has opposite effects on CETP and HDL-cholesterol responses to dietary cholesterol (J Lipid Res 1993)
- ApoE boosts CETP-mediated lipid exchange by raising the affinity of VLDL for CETP (J Lipid Res 1993)
- Probucol significantly raises CETP activity while shrinking large LDL and both HDL subfractions (Artery 1993)
- CETP generates pre-beta HDL-like particles from alpha HDL, completing a cyclical model with LCAT (J Lipid Res 1992)
- Elevated plasma CETP correlates with cholesteryl ester-enriched VLDL and normalizes with corticosteroid treatment in nephrotic syndrome (J Lipid Res 1992)
- CETP drives HDL apolipoproteins A-I and A-II onto LDL particles, an effect greatly amplified by oleic acid (Biochim Biophys Acta 1992)
- Primate CETP transgene dose-dependently depletes large HDL1/HDL2 particles in mice, correlating -0.81 with plasma apoA-I levels (Arterioscler Thromb 1992)
- CETP activity is twofold higher in familial hypercholesterolemia, linked to worse IDL and HDL composition (Horm Metab Res 1992)
- Alcohol abusers have 27 percent lower plasma CETP concentration and 22 percent lower CETP activity than controls (J Lipid Res 1992)
- CETP and hepatic lipase together shed apoA-I from HDL, which reassembles into new discoidal particles (Biochim Biophys Acta 1992)
- ApoA-II blocks CETP-driven conversion of reconstituted HDL into small particles, while apoA-I-only HDL splits into both large and small particles (J Lipid Res 1992)
- Hepatic sinusoidal cells, not hepatocytes, are the principal source of CETP mRNA in primate liver (J Biol Chem 1991)
- Medium-chain saturated fatty acids boost CETP-driven formation of very small HDL particles, while arachidonic acid blocks it (Biochim Biophys Acta 1991)
- CETP-mediated cholesteryl ester transfer rises with acyl chain length while selective cellular uptake falls, an inverse relationship across four cell types (J Lipid Res 1991)
- Probucol raises plasma CETP by 64 percent while lowering HDL cholesterol, consistent with enhanced remnant-pathway reverse cholesterol transport (Arterioscler Thromb 1991)
- A new immunoassay confirms plasma CETP protein, not just activity, is absent in patients with CE transfer deficiency (Clin Chim Acta 1990)
- CETP activity falls 15 percent in hypothyroidism, tracking changes in HDL lipid composition (Eur J Clin Invest 1990)
- Alcoholics have 28 percent lower CETP activity than controls, explaining their elevated HDL cholesterol (Eur J Clin Invest 1990)
- CETP is identical to the mysterious HDL conversion factor, and fatty acids greatly amplify its particle-shrinking effect (Biochim Biophys Acta 1990)
- HDL triglyceride and free cholesterol content noncompetitively inhibit CETP, while HDL apoprotein composition uncompetitively modulates it (J Lipid Res 1989)
- CETP TaqI B polymorphism shows a dosage effect on apoA-I levels, limited to nonsmokers (Clin Genet 1989)
- Meta-analysis of 3,512 patients: obicetrapib added to ezetimibe nearly doubles LDL-C lowering seen with obicetrapib alone, but adds nothing to statins (Cardiol Rev 2026)
- Meta-analysis of three RCTs in 3,286 patients confirms obicetrapib effects on LDL-C, apoB and HDL-C with no excess adverse events (Ann Med Surg 2026)
- CETP inhibitor trials reframe the HDL hypothesis around apoB lowering rather than HDL-C raising (Drugs 2026)
- Meta-analysis of 3,088 patients: obicetrapib cuts LDL-C by 32% and Lp(a) by 36% with no excess adverse events (Vasc Dis 2026)
- Meta-analysis of 657 patients: obicetrapib combination therapy, especially with ezetimibe at 10mg, beats obicetrapib monotherapy for LDL-C lowering (Semergen 2026)
- Review weighs CETP-expressing hamsters against mice and rats for translational relevance in atherosclerosis modeling (Int J Mol Sci 2025)
- Meta-analysis of nine RCTs in 3,516 patients confirms obicetrapib lowers LDL-C by 37% and Lp(a) by 41% with no excess adverse events (Cardiol Rev 2025)
- Review surveys why raising HDL with CETP inhibitors and apoA1 infusion has failed to cut cardiovascular events (Clin Med Res 2025)
- CETP rs3764261 T allele, a known atherosclerosis-protective variant, is linked to protection against eye inflammation after brolucizumab (Genes 2025)
- Genetic CETP deficiency review: heterozygotes have lower ASCVD risk, homozygotes show no excess risk, and very high HDL-C raises AMD questions (J Atheroscler Thromb 2025)
- Meta-analysis of seven studies: adding a CETP inhibitor to high-intensity statins significantly raises HDL-C and lowers LDL-C with no added adverse events (Front Endocrinol 2025)
- CETP damages perivascular fat function in male mice through oxidative stress and inflammation, but preserves it in females (Function (Oxf) 2024)
- CETP variants, an update: a review maps how CETP structure, animal models and SNPs shape lipid profiles and cardiovascular risk (Curr Pharm Des 2024)
- HDL as a treatment target: a review says the obicetrapib outcomes trial will help decide whether to abandon the HDL hypothesis for good (Curr Atheroscler Rep 2023)
- Genome-wide interaction analysis pinpoints a CETP variant that modifies how sedentary behavior affects HDL cholesterol (Nutrients 2023)
- CETP activity rises stepwise from underweight to overweight/obese children, tracking with visceral-adiposity and lipid-accumulation indexes (Nutr Metab Cardiovasc Dis 2023)
- Late-onset preeclampsia blunts the normal second-trimester decline in HDL cholesterol, apoA-I, and CETP activity seen in low-risk pregnancies (Int J Mol Sci 2023)
- Sex and BMI modify how much genetically lower CETP raises HDL-C and lowers LDL-C, though not cardiovascular outcomes (Genet Epidemiol 2023)
- Meta-analysis of 70 studies confirms CETP rs708272 is linked to lower coronary artery disease risk and higher HDL cholesterol (Front Cardiovasc Med 2023)
- CETP missense variants raise HDL cholesterol mainly by reducing protein secretion, not intrinsic lipid-transfer activity (PLoS One 2023)
- Review asks whether CETP inhibitors are still worth pursuing after two decades of disappointing trials (Curr Atheroscler Rep 2022)
- Dalcetrapib and anacetrapib generate large apoE-containing HDL particles that can bind the hepatic LDL receptor (J Lipid Res 2023)
- A review asks whether genomic analyses and post hoc trial insights can revive CETP inhibitors for cardiovascular prevention after past disappointments (Curr Opin Lipidol 2022)
- In the multi-ethnic MESA cohort, higher HDL cholesterol, HDL particle number, and CETP mass predict lower long-term aortic valve calcification (Arterioscler Thromb Vasc Biol 2022)
- A randomized trial finds lycopene supplements boost HDL PON-1 antioxidant activity and lower CETP activity in HDL2 and HDL3 without changing particle size (Front Nutr 2022)
- Long-term matcha green tea worsens reverse cholesterol transport and fails to prevent diet-induced arteriosclerosis in rabbits (Mol Nutr Food Res 2021)
- The low-density lipoprotein receptor is required for CETP to control triglyceride metabolism in mice of both sexes (Physiol Rep 2021)
- Human ApoC1 transgene reduces atherosclerosis in rabbits partly by inhibiting CETP activity (Atherosclerosis 2021)
- Sepsis rapidly suppresses LCAT and CETP activity while raising PLTP and endothelial lipase, with LCAT activity predicting mortality (Front Cell Dev Biol 2021)
- A randomized trial finds omega-3 supplementation significantly lowers CETP activity and shrinks small HDL in high-cardiovascular-risk patients (Front Nutr 2021)
- Desmodium gyrans extract raises HDL-promoting SR-B1 and apoA-I while lowering CETP expression in liver cells (Indian J Pharmacol 2021)
- Intensive insulin therapy in newly diagnosed type 1 diabetes progressively suppresses serum CETP and PLTP over the first year (Nutr Metab Cardiovasc Dis 2021)
- A loss-of-function CETP variant raises HDL cholesterol without raising ApoA1 or protecting against heart attack in Chinese patients (Nutr Metab Cardiovasc Dis 2021)
- CETP shifts HDL toward small, immature particles in coronary heart disease patients (Clin Lab 2020)
- CETP impairs triglyceride clearance in male mice through androgen receptor signalling (Lipids 2020)
- First Samoan genome-wide association study confirms CETP-HDL cholesterol link in a previously unstudied Polynesian population (J Hum Genet 2020)
- The largest cohort study on the topic finds physical activity boosts HDL cholesterol efflux capacity, and shows a U-shaped CETP response in people with diabetes (Eur J Prev Cardiol 2021)
- An undesirable postprandial triglyceride response enhances CETP-mediated cholesteryl ester transfer to chylomicrons and reduces hepatic HDL cholesteryl ester uptake (Biomolecules 2020)
- CETP variant rs708272 shows a striking association with childhood HDL cholesterol and triglycerides in a pan-European cohort (Sci Rep 2020)
- A review argues the failure of CETP inhibitors and niacin to reduce cardiovascular events undermines the HDL cardioprotection hypothesis (Drugs 2020)
- In 1,855 Ghanaian adults, CETP variant rs17231520 is the leading genetic signal for HDL cholesterol, replicating a finding rare in West African cohorts (Front Genet 2020)
- Homozygous B4GALT1 mutations cause CETP hypoglycosylation and reduced activity, yielding larger HDL particles (J Inherit Metab Dis 2020)
- Even NMR-measured HDL particle concentration, not just HDL-C, failed to predict cardiovascular risk in dal-Outcomes (Am Heart J 2020)
- CETP variant rs708272 doubles the risk of myocardial infarction in men from Western Siberia (Biomolecules 2019)
- CETP redirects cholesterol elimination away from the gut and toward bile, steering HDL cholesteryl esters differently than those from LDL (Arterioscler Thromb Vasc Biol 2019)
- Rare CETP variants found in most Korean adults with extremely high HDL cholesterol, but do not alter cholesterol efflux (Sci Rep 2019)
- CETP activity does not track carotid intima-media thickness once diabetes control is poor, unlike in well-controlled patients (Acta Diabetol 2019)
- A year of higher legume and fish intake lowers CETP activity in a large cardiovascular-risk cohort (Mol Nutr Food Res 2019)
- Genetic CETP deficiency loads HDL with apoE, apoC-III, ANGPTL3 and complement proteins, offering a clue why high HDL-C doesn't protect these patients (J Clin Lipidol 2019)
- Review contrasts disappointing CETP antagonists with the anti-inflammatory promise of the CETP agonist probucol (Atherosclerosis 2018)
- A randomized trial finds baru almonds reduce waist circumference and CETP expression while raising HDL in overweight women (Nutrition 2018)
- Diet-induced weight loss fails to improve HDL cholesterol efflux or cholesteryl ester transfer in obese men (Atherosclerosis 2018)
- Weight gain prevention counteracts the HDL-lowering effect of CETP variant rs3764261 in young adults, randomized trial finds (Nutr Metab Cardiovasc Dis 2018)
- CETP variant rs708272 raises acute coronary syndrome risk and shifts HDL subclass cholesterol content (Lipids 2018)
- An 8-week randomized trial finds Cuban policosanol lowers blood pressure and CETP activity by 20% while boosting HDL function in healthy women (Oxid Med Cell Longev 2018)
- Aerobic exercise reshapes arterial and macrophage gene expression toward atheroprotection in CETP-transgenic mice, independent of changes in CETP activity (Front Physiol 2018)
- Statin-driven normalisation of HDL lipid composition lags behind LDL and apoB reduction, revealing role of CETP (J Clin Lipidol 2018)
- Same drug, opposite effect: dalcetrapib raised HDL in rabbits but cut it 48% in monkeys, while anacetrapib behaved consistently across species (J Lipid Res 2017)
- Torcetrapib raised HDL ApoC-III and LpA-I subclasses without altering ApoB particles in ILLUMINATE (Am J Cardiol 2017)
- A Mediterranean diet enriched with olive oil lowers CETP activity and improves multiple HDL functions in the year-long PREDIMED trial (Circulation 2017)
- CETP activity is highest in cord and maternal blood of growth-restricted neonates, alongside multiple proatherogenic lipoprotein changes (J Clin Lipidol 2017)
- A year of Mediterranean diet raises HDL cholesterol and lowers triglycerides specifically in carriers of the CETP rs3764261 T allele, CORDIOPREV trial finds (Clin Nutr 2018)
- Meta-analysis of over 40,000 subjects confirms CETP TaqIB B1 allele raises ischemic cardiovascular disease risk and lowers HDL cholesterol (Int J Environ Res Public Health 2016)
- Urban versus rural residence predicts opposite CETP and PLTP activity patterns in Polish men, independent of smoking and alcohol use (Arch Med Sci 2016)
- Active rheumatoid arthritis is linked to higher CETP activity and impaired paraoxonase function, with apoA-I predicting arterial stiffness (Atherosclerosis 2016)
- Pigs bred for high CETP activity show altered hepatic expression of inflammatory genes and microRNAs, with gender and breed effects (Mamm Genome 2016)
- A high-dose tetanus toxoid-CETP vaccine lowers CETP activity and raises HDL-C in rabbits but fails to reduce atherosclerotic lesions (Biomed Pharmacother 2016)
- Active hepatitis C infection is associated with higher serum CETP and HDL triglyceride than after viral eradication (World J Hepatol 2016)
- CETP expression does not alter glucose tolerance, insulin secretion, or tissue glucose uptake in transgenic mice across multiple conditions (Lipids Health Dis 2016)
- Extended-release niacin/laropiprant abolishes the postprandial rise in CETP activity and boosts HDL's fecal cholesterol removal capacity (Arterioscler Thromb Vasc Biol 2015)
- Resequencing the entire CETP gene uncovers rare variants that independently affect HDL cholesterol in both whites and African blacks (Metabolism 2016)
- A review argues the failure of niacin to reduce cardiovascular events, alongside CETP inhibitor trial results, exposes the flaws of the HDL cholesterol hypothesis (Curr Atheroscler Rep 2015)
- Two linked upstream CETP variants have opposite effects on gene expression via disrupted transcription factor binding sites (Pharmacogenet Genomics 2015)
- The CETP B2 allele is linked to lower LDL cholesterol specifically in black, not white, South African women (Atherosclerosis 2015)
- A review argues cholesterol efflux capacity, not HDL cholesterol, is the more meaningful marker after CETP inhibitor and niacin trials failed to reduce cardiovascular outcomes (Prog Cardiovasc Dis 2015)
- CETP concentration is elevated and inversely correlates with hemoglobin in women with iron deficiency anaemia (Clin Lab 2015)
- Fine-mapping of the CETP region identifies five novel variants, including a common intronic insertion, linked to HDL-C (NPJ Aging Mech Dis 2015)
- Niacin plus laropiprant, but not fenofibrate, significantly lowers CETP and LCAT activity in type 2 diabetic patients with low HDL (Atherosclerosis 2015)
- Review from the discoverer of CETP deficiency in Japan surveys anacetrapib and evacetrapib as candidate cures for atherogenic dyslipidemia (Mol Cells 2014)
- Cholesteryl ester diffusion and self-association within the HDL phospholipid bilayer set the pace of CETP-mediated lipid transfer (Arch Biochem Biophys 2014)
- Dalcetrapib raises plasma campesterol only in patients with intact ABCA1 and ApoA1, a crossover trial finds (Lipids 2014)
- CETP TaqIB B2 homozygotes get the strongest heart-protective benefit from moderate alcohol intake, replicating a prior finding in men (Alcohol 2014)
- Increased fruit and vegetable intake lowers serum amyloid A and CETP activity in HDL subfractions across two randomized trials (Br J Nutr 2014)
- Ten CETP locus SNPs are among the strongest genetic determinants of HDL cholesterol variability in a Latvian population (Meta Gene 2014)
- HDL from patients with CETP- or hepatic-lipase-deficiency hyperalphalipoproteinemia is not dysfunctional and shows enhanced cholesterol efflux from macrophages (Atherosclerosis 2014)
- Very low plasma CETP is linked to impaired HDL cholesterol efflux in the LURIC cohort (Eur J Clin Invest 2014)
- CETP TaqIB B2B2 genotype raises atrial fibrillation risk, especially in postmenopausal women with higher triglycerides (J Atr Fibrillation 2014)
- HDL from genetically CETP-deficient carriers is worse at activating eNOS, despite normal cholesterol-efflux capacity (PLoS One 2014)
- The CETP rs1532624 AA genotype has lower CETP activity, higher HDL-C, but a weaker LDL-C response to statins in Jordanian patients (Curr Mol Pharmacol 2013)
- CETP Taq1B B1/B1 genotype predicts a favorable triglyceride/HDL-C response to kiwifruit in hypercholesterolaemic men (Br J Nutr 2013)
- 10-Dehydrogingerdione raises HDL cholesterol by suppressing CETP and curbs oxidative and inflammatory markers in rabbits (Atherosclerosis 2013)
- CETP B1B1 genotype tracks with lower HDL cholesterol from birth through age 5-6 in children at cardiovascular risk (Med Sci Monit 2013)
- CETP I405V polymorphism is an independent risk factor for endometriosis in a case-control study of women (Gynecol Endocrinol 2013)
- HDL3 reduces macrophage ER stress and partially restores apoE and CETP secretion suppressed by tunicamycin (Biochem Biophys Res Commun 2013)
- Fenofibrate and extended-release niacin raise HDL cholesterol equally but reshape HDL particle size differently, without improving cholesterol efflux (J Clin Lipidol 2013)
- CETP is the single most common genetic factor influencing HDL cholesterol in the Latvian population, ten-SNP association study finds (PLoS One 2013)
- Anacetrapib-raised HDL retains its anti-inflammatory effect on endothelial cells (Biochim Biophys Acta 2013)
- Novel CETP promoter variants found in hyperalphalipoproteinemia patients sharply cut gene transcriptional activity (Clin Chim Acta 2013)
- Molecular dynamics simulation reveals CETP forms a more flexible structure in solution than in the crystal, supporting a continuous internal tunnel (Proteins 2012)
- CETP inhibition alone fails to boost reverse cholesterol transport in hamsters unless paired with the LDL-lowering drug berberine (Arterioscler Thromb Vasc Biol 2013)
- Higher CETP mass independently predicts a lower leukocyte count, and switching atorvastatin to pitavastatin raises CETP mass by 8.8 percent (Am J Cardiovasc Drugs 2012)
- Higher endogenous CETP activity boosts cholesterol efflux capacity via pre-beta1-HDL in women (Arterioscler Thromb Vasc Biol 2012)
- Review weighs whether CETP inhibition can rescue the HDL-raising hypothesis after AIM-HIGH, HERS, ILLUMINATE, and dal-OUTCOMES (Curr Treat Options Cardiovasc Med 2012)
- A 12-week lycopene trial lowers serum CETP activity and boosts LCAT and paraoxonase-1 activity in overweight middle-aged adults (J Nutr Biochem 2013)
- A distinct HDL-like particle seen in complete genetic CETP deficiency is absent in dalcetrapib-treated volunteers (Curr Vasc Pharmacol 2012)
- CETP -629 AA genotype is enriched in metabolic syndrome patients and linked to lower CETP but higher LDL-C and total cholesterol (Mol Biol Rep 2012)
- Common CETP genetic variants do not alter how well the apoB/apoA-I ratio predicts first major cardiovascular events compared with TC/HDL-C (J Clin Lipidol 2012)
- ApoC1's natural inhibition of plasma CETP is blunted in dyslipidaemic coronary artery disease patients (J Lipid Res 2012)
- Resequencing finds rare CETP mutations and a common variant far more often in Thai patients with very high HDL cholesterol (Am J Cardiol 2012)
- Knocking down hepatic SR-BI raises CETP-mediated cholesteryl ester transfer from HDL to apoB lipoproteins and halves atherosclerotic lesion area in rabbits (Atherosclerosis 2012)
- Adding dalcetrapib to pravastatin reshapes HDL composition and boosts two cholesterol efflux pathways in a phase IIb dose-ranging study (Am Heart J 2012)
- Non-HDL-C and insulin resistance predict high CETP activity in patients at risk for type 2 diabetes (Clin Biochem 2012)
- A Nature Reviews Endocrinology paper argues HDL actively regulates glucose metabolism, positioning CETP inhibitors for rapid clinical translation to diabetes (Nat Rev Endocrinol 2012)
- CETP inhibition boosts the cholesterol-removing power of large HDL2b particles after a meal, but not their delivery to the liver (Atherosclerosis 2012)
- Ezetimibe lowers CETP mass by 20 percent in most type 2 diabetes patients, tracking with HDL subclass shifts (Endocr J 2012)
- Women with angina pectoris show enhanced CETP activity in both HDL and LDL alongside impaired HDL antioxidant enzymes (Int J Mol Med 2011)
- ApoA-I stimulates CETP and apoE secretion from lipid-loaded macrophages via NF-kB inhibition and PKA activation (Biochem Biophys Res Commun 2011)
- A 16-week very-low-calorie diet in obese type 2 diabetics cuts plasma CETP by 18% and raises apoA-I by 16%, without improving HDL cholesterol efflux (Diabetes Care 2011)
- Unlike torcetrapib, dalcetrapib shifts cholesterol homeostasis toward absorption markers rather than synthesis markers (Atherosclerosis 2011)
- PPAR-delta agonist GW501516 lowers CETP activity alongside broad apoB and apoC-III kinetic changes in obese dyslipidemic men (J Clin Endocrinol Metab 2011)
- CETP actually boosts the ability of HDL to block LDL oxidation, a finding that may help explain why torcetrapib failed to slow vascular disease (IUBMB Life 2011)
- High CETP is an independent negative determinant of LDL size and tracks with CAD prevalence in haemodialysis patients (Nephrology (Carlton) 2011)
- CETP concentration is higher in coronary heart disease patients but is not itself an independent predictor of LDL particle size (Bosn J Basic Med Sci 2011)
- Familial hypercholesterolemia patients show elevated CETP-mediated cholesteryl ester transfer and defective reverse cholesterol transport (Arterioscler Thromb Vasc Biol 2011)
- Aerobic exercise boosts macrophage-to-feces reverse cholesterol transport in CETP-transgenic mice without changing CETP activity (Lipids 2011)
- Tree shrew CETP structure-function mapping identifies Asn110 as essential for secretion and residues 344/452 as essential for cholesteryl ester transfer (Lipids 2011)
- A novel CETP promoter deletion causing CETP deficiency does not impair HDL function in reverse cholesterol transport (Atherosclerosis 2011)
- Oxazolidinone-substituted benzoxazole CETP inhibitors raise HDL cholesterol up to 33 mg/dl in mice while avoiding hERG channel binding (Bioorg Med Chem Lett 2011)
- The original benzoxazole scaffold-redesign paper discovers CETP inhibitor 11v, raising HDL cholesterol by 24 mg/dl in mice (Bioorg Med Chem Lett 2011)
- CETP mutations raise HDL 27-hydroxycholesterol, and CETP mass correlates more strongly with 27OHC-ester than cholesteryl ester transfer (Atherosclerosis 2010)
- Naturally low CETP and PLTP activity may explain atherosclerosis resistance in tree shrews and Beijing ducks (Lipids Health Dis 2010)
- Up-titrated rosuvastatin and atorvastatin both significantly reduce CETP mass and activity in low-HDL-C cardiovascular patients (Curr Med Res Opin 2010)
- Postprandial lipemia boosts HDL2's cholesterol efflux capacity but raises CETP-mediated transfer and impairs hepatic HDL delivery in type IIB hyperlipidemia (J Lipid Res 2010)
- Gastric bypass weight loss in obese women improves HDL remodeling, with CETP mass changes tracking glucose improvement but not fat-mass loss (J Lipid Res 2010)
- CETP variants raise HDL cholesterol by up to 14 percent regardless of diet, alcohol, or diabetes status in a high-risk Mediterranean population (J Lipid Res 2010)
- Acute Epstein-Barr virus infection transiently elevates CETP activity alongside other atherogenic lipid changes that resolve within four months (Atherosclerosis 2010)
- A review argues CETP inhibitor trial failures show HDL-C elevation alone is insufficient, motivating apoA-I-targeted therapies instead (Drugs 2010)
- CETP TaqIB fails to protect against coronary heart disease over 10 years despite raising HDL cholesterol, and even raises risk in drinkers (Atherosclerosis 2010)
- Thirty-five days of bed rest raises plasma CETP by 27% independently of fat mass in healthy men (J Clin Endocrinol Metab 2010)
- A review explains why CETP-expressing hamsters, not mice, are the preferred preclinical model for testing reverse-cholesterol-transport drugs (Curr Opin Investig Drugs 2010)
- CETP TaqIB B1B1 men are most responsive to a high-carbohydrate low-fat diet's HDL-raising effect in young Chinese adults (J Nutr Biochem 2010)
- Metabolic syndrome raises serum CETP activity 38% alongside dysfunctional, antioxidant-depleted HDL (Int J Mol Med 2010)
- HDL from patients on high-dose torcetrapib removes more cholesterol from macrophages, correlating with the atheroma regression seen on the drug (Am J Cardiol 2009)
- The novel SR-BI inhibitor ITX5061 raises HDL cholesterol by 20% in humans and reduces atherosclerosis in mice regardless of CETP expression (Arterioscler Thromb Vasc Biol 2009)
- Rare CETP-deficient case reveals independent control of remnant triglyceride and cholesterol after a fat load (Ann Clin Biochem 2009)
- Two new CETP and LIPC gene mutations identified as causes of extremely high HDL cholesterol in Thai patients (Metabolism 2009)
- Brucella infection raises CETP activity and leaves an unresolved atherogenic lipid profile four months after treatment (J Lipid Res 2009)
- The CETP SNP rs1800775 explains more variance in HDL cholesterol than any other single lipid gene variant studied in older adults (Eur Heart J 2009)
- Reducing proteinuria lowers LDL cholesterol together with plasma CETP mass, but also lowers HDL cholesterol (Expert Opin Ther Targets 2009)
- CETP locus generalizes as a blood-lipid determinant across black, Mexican American, and white US populations (Circ Cardiovasc Genet 2009)
- CETP TAQIB and I405V rare alleles are modestly associated with reduced obesity risk in Chinese adults, largely via HDL levels (Acta Diabetol 2009)
- High-dose atorvastatin reduces pre-beta-HDL formation and CETP activity in type 2 diabetes, mediated by falling PLTP activity and triglycerides, not CETP (Biochim Biophys Acta 2009)
- Torcetrapib raises apolipoprotein A-II levels by slowing its clearance and shifting it into a different HDL subpopulation (J Lipid Res 2009)
- A PADRE T-cell epitope CETP vaccine paired with CpG adjuvant elicits stronger anti-CETP antibody responses than the CETi-1 vaccine in mice and rabbits (Hum Vaccin 2009)
- CETP-mediated cholesterol transfer cannot substitute for SR-BI in adrenal steroid production (J Lipid Res 2009)
- Serum cholesterol efflux capacity is preserved or enhanced in genetically CETP-deficient patients (Clin Chim Acta 2008)
- Torcetrapib partly restores healthy HDL2 and HDL3 function in type IIB hyperlipidemia, boosting cholesterol efflux by up to 38 percent (Arterioscler Thromb Vasc Biol 2009)
- A review notes a meta-analysis linking CETP-lowering alleles to reduced coronary heart disease, distinct from the off-target failure of torcetrapib (J Lipid Res 2009)
- Only triglyceride-rich apoB lipoprotein subclasses accept cholesteryl esters transferred by CETP (Eur J Clin Invest 2008)
- First CETP gene mutations identified in Italian patients with extremely high HDL cholesterol, including two premature-stop-codon variants (Atherosclerosis 2009)
- Updated pooled analysis finds the CETP B2 allele may raise, not lower, cardiovascular risk in the general population despite higher HDL cholesterol (Pharmacogenomics 2008)
- A fat load raises CETP mass and cholesteryl ester transfer while lowering HDL cholesterol in obese metabolic syndrome men, unaffected by statin or statin-ezetimibe treatment (Clin Endocrinol 2008)
- A Nature Reviews Drug Discovery analysis asks whether the torcetrapib failure means functional quality of HDL matters more than its circulating quantity (Nat Rev Drug Discov 2008)
- Glucocorticoid replacement erases the CETP promoter variant's link to HDL cholesterol in hypopituitary patients (Clin Endocrinol (Oxf) 2008)
- Alcohol only reduces heart disease risk in CETP TaqIB B2 carriers, especially among women, two large US cohort studies find (Eur Heart J 2008)
- HIV infection raises CETP mass and activity and redirects cholesterol away from HDL (Atherosclerosis 2007)
- Torcetrapib cuts postprandial VLDL-1 by 40 percent and reduces its atherogenic cholesteryl-ester content in type IIB hyperlipidemia (Arterioscler Thromb Vasc Biol 2008)
- Smoking advances first heart attack by up to 9 years in CETP TaqIB B1 carriers, but not in B2B2 homozygotes (Ann Noninvasive Electrocardiol 2007)
- CETP overexpression in transgenic mice does not impair macrophage reverse cholesterol transport or HDL's LDL-antioxidant activity (Atherosclerosis 2007)
- Elevated CETP levels track with oxidized LDL in dyslipidemic patients (Clin Biochem 2007)
- CETP I405V VV genotype cuts myocardial infarction risk in men by 43 percent in the Rotterdam Study (Eur J Cardiovasc Prev Rehabil 2007)
- White women with a CETP -629 A/A genotype gain the most HDL cholesterol from 20 weeks of endurance training (Physiol Genomics 2007)
- The first molecular characterization of avian CETP finds chicken CETP activity rises with dietary cholesterol and falls with egg-laying maturity, likely regulated by estrogen (Comp Biochem Physiol B 2007)
- CETP deficiency sharply blunts the post-meal triglyceride spike and remnant lipoprotein formation (Atherosclerosis 2008)
- A critical appraisal argues high CETP may actually lower cardiovascular risk when triglycerides are low, complicating the case for CETP inhibition (Eur J Clin Invest 2007)
- A novel CETP splice-site mutation causes isolated high HDL cholesterol in Caucasians, distinct from ordinary hyperalphalipoproteinemia (J Lipid Res 2007)
- Plasma CETP activity tracks hepatic cholesterol synthesis machinery in humanized transgenic mice (Clin Exp Pharmacol Physiol 2006)
- CETP expression amplifies hepatic cholesteryl ester and triglyceride accumulation from apoC-I deficiency by up to 302% in mice (J Lipid Res 2007)
- Fenofibrate lowers CETP activity while raising PLTP activity, reshaping apoB-100 kinetics in metabolic syndrome (Clin Sci (Lond) 2006)
- A review describes proof-of-principle preclinical and clinical results for a semi-annual CETP vaccine to raise HDL and address unmet cardiovascular need (Vascul Pharmacol 2006)
- Partial, not complete, CETP inhibition preferentially blocks lipid transfer to LDL while sparing HDL flux (Atherosclerosis 2006)
- Torcetrapib raises large alpha-1 HDL particles by more than 50 percent in humans, mainly by slowing ApoA-I breakdown (Curr Opin Lipidol 2006)
- CETP expression speeds hepatic uptake of HDL cholesteryl ester but leaves VLDL secretion and biliary cholesterol excretion unchanged in mice (Atherosclerosis 2007)
- Atorvastatin lowers CETP activity and raises paraoxonase without changing HDL cholesterol (Clin Biochem 2006)
- CETP is one of only four genes with consistent lipid effects across sex and race in the CARDIA cohort (Arterioscler Thromb Vasc Biol 2006)
- CETP Taq1B B1 allele linked to worse lipid profile and higher blood pressure in kidney transplant patients (Transplant Proc 2006)
- CETP mass is elevated in men, but not women, with metabolic syndrome, and tracks inversely with LDL particle size in both sexes (Obesity 2006)
- ApoE-containing HDL activates LCAT less efficiently than apoA-I-HDL and is remodeled by CETP into large fusion products instead of small lipid-poor particles (J Lipid Res 2006)
- Plasma cholesteryl ester transfer, driven by CETP and triglycerides, predicts carotid intima-media thickness in type 2 diabetes (Diabetes 2005)
- Human apoA-I overexpression strips apoC-I from HDL and removes most of HDL's natural CETP-inhibitory capacity in transgenic rats (J Lipid Res 2005)
- Type 1 diabetics show enhanced cellular cholesterol efflux and higher CETP activity, and simvastatin lowers HDL cholesterol-linked CETP transfer without boosting efflux further (Diabetologia 2005)
- High triglycerides nearly halve the HDL-raising benefit of a protective CETP promoter variant, large PREVEND study finds (J Clin Endocrinol Metab 2005)
- Torcetrapib raises apolipoprotein A-I in alpha1-migrating HDL by up to 382 percent at twice-daily dosing, without changing fecal sterol excretion (Arterioscler Thromb Vasc Biol 2005)
- High-dose simvastatin lowers CETP activity dose-dependently and normalizes chylomicron remnant clearance in premature CAD (Atherosclerosis 2005)
- A low-fat, low-cholesterol diet lowers CETP activity in type 1 diabetics without harming cholesterol efflux (Scand J Clin Lab Invest 2005)
- A newly characterized CETP promoter variant raises HDL cholesterol specifically in African Americans by weakening a transcription-factor binding site (Clin Genet 2004)
- CETP TaqB1B1 genotype linked to higher LDL cholesterol in Chinese coronary heart disease patients (Chin Med J (Engl) 2004)
- SR-BI corrects the atherogenic, cholesteryl-ester-rich HDL seen in CETP deficiency (Atherosclerosis 2004)
- First CETP-specific antibody fragments enable a new quantification assay and link plasma CETP to body fat mass (Clin Chem Lab Med 2004)
- Elderly men carrying a CETP mutation trend toward the lowest heart disease rates in a 7-year Honolulu Heart Program follow-up (J Lipid Res 2004)
- Type 2 diabetes lowers CETP specific activity while total CETP mass and activity remain unchanged, unlike PLTP which rises with triglycerides and obesity (Scand J Clin Lab Invest 2004)
- CETP deficiency produces giant HDL particles carrying nearly every major apolipoprotein except apoA-IV (J Lipid Res 2004)
- Hepatic lipase TT genotype protects against vascular disease only in hemodialysis patients with high CETP levels (Kidney Int 2003)
- Review names CETP-driven triglyceride enrichment of HDL as a key mechanism of low HDL in insulin resistance (Clin Biochem 2003)
- CETP expression completely abolishes LXR-agonist-induced HDL enlargement in mice (J Biol Chem 2003)
- Intravenous apoA-I/phosphatidylcholine discs raise plasma CETP concentration by 29.7% and cholesterol esterification rate by 69.5% within 12 hours in healthy men (Arterioscler Thromb Vasc Biol 2003)
- Red pepper supplementation lowers CETP activity and improves the lipid profile in cholesterol-fed rabbits (Clin Chim Acta 2003)
- CETP I405V genotype determines whether dietary plant sterols lower cholesterol and CETP concentration (J Nutr 2003)
- Chiral optimization yields the most potent acyclic CETP inhibitor reported, with an IC50 of 0.77 nanomolar in buffer (J Med Chem 2003)
- Bezafibrate lowers CETP activity by 12% and cholesteryl ester transfer by 37% alongside reduced insulin resistance in hypertriglyceridemia (J Lipid Res 2003)
- Short-term hypothyroidism significantly lowers serum CETP concentration but not activity, decoupled from HDL2:HDL3 and LDL-cholesterol correlations seen in controls (Clin Endocrinol 2003)
- CETP activity rises 47% in impaired glucose tolerance and correlates with triglycerides, HDL composition, and apoA-I catabolic rate (Croat Med J 2003)
- Full resequencing pinpoints the specific CETP promoter and repeat variants most strongly linked to CETP mass and HDL cholesterol (Atherosclerosis 2003)
- Review surveys CETP as both an unresolved genetic risk marker and a newly validated drug target (Curr Opin Lipidol 2003)
- Higher CETP activity in Hispanic postmenopausal women tracks with abdominal fat, not ethnicity itself (Metabolism 2003)
- Antisense knockdown of CETP in HepG2 cells raises cholesterol efflux to apoA-I but impairs SR-BI-mediated HDL cholesteryl ester uptake by the liver (Am J Physiol Endocrinol Metab 2003)
- CETP mutations explain most, but not all, cases of extremely high HDL cholesterol in 624 Japanese patients (Atherosclerosis 2003)
- CETP variants cannot explain why Asian Indians have both the highest heart disease rates and lowest HDL cholesterol in Singapore (Clin Genet 2003)
- CETP Taq1B B1B1 genotype independently predicts coronary artery disease in Koreans (Clin Genet 2003)
- Two newly discovered CETP mutations block protein secretion, explaining more than 60 percent of severe high-HDL cases in Japan (J Lipid Res 2002)
- ApoCI deficiency doubles CETP-driven HDL cholesteryl ester depletion in transgenic mice (J Biol Chem 2002)
- D442G CETP mutation raises HDL cholesterol in Korean postmenopausal women but does not alter the HDL response to hormone therapy (Korean J Intern Med 2002)
- Review focuses on CETP inhibitors and ABC1-inducing nuclear receptor agonists as new HDL-raising drug approaches (Mini Rev Med Chem 2002)
- Adding CETP shifts lipoproteins toward VLDL and IDL/LDL, and appears to blunt diabetes-driven hyperlipidemia in LPL-deficient mice (J Lipid Res 2002)
- CETP activity is an independent predictor of LDL particle size in familial combined hyperlipidemia, alongside triglycerides and hepatic lipase (J Lipid Res 2002)
- CETP TaqIB B2 carriers have higher HDL cholesterol but no lower heart attack risk in a large Physicians Health Study cohort (Atherosclerosis 2002)
- Review explains why hypothyroidism keeps HDL normal or high via thyroid-hormone-regulated CETP suppression (Thyroid 2002)
- CETP activity does not predict LDL buoyancy in women, but CETP TaqIB genotype does predict CETP mass and HDL3 cholesterol (Arterioscler Thromb Vasc Biol 2002)
- Serum CETP concentration falls in postmenopausal Chinese women and correlates positively with estradiol, negatively with FSH (Clin Chim Acta 2001)
- CETP activity runs 2-3 times higher in hyperlipoproteinemia patients, peaking in Type V dyslipidemia (Atherosclerosis 2001)
- CETP EcoN1 GG genotype linked to coronary heart disease risk in a Taiwanese population survey (Atherosclerosis 2001)
- CETP TaqIB predicts heart attack risk and a 2-year later age of onset, but a linked promoter variant does not, Reykjavik Study finds (Atherosclerosis 2001)
- The CETP D442G mutation raises HDL cholesterol in adults but not children, first pediatric study of this variant finds (Pediatr Res 2001)
- Psyllium fiber lowers CETP activity 18% regardless of sex, while its triglyceride effects diverge by sex and menopausal status (Am J Clin Nutr 2001)
- CETP transgenic mice reproduce the human-like cholesterol response to dietary fat type, with MUFA and PUFA lowering plasma cholesterol (Br J Nutr 2001)
- Growth hormone replacement transiently lowers CETP concentration and LDL cholesterol together, revealing a shared regulatory link (Lipids 2001)
- CETP activity divides six animal species into two groups: low-CETP mouse/rat/dog with high HDL-C, versus high-CETP hamster/rabbit/monkey with low HDL-C (Biol Pharm Bull 2001)
- Polyunsaturated fatty acids arachidonic, eicosapentaenoic, and docosahexaenoic halve CETP mRNA expression in HepG2 liver cells (Lipids 2001)
- CETP activity differences do not explain how margarine and butter diets change HDL cholesterol (J Lipid Res 2001)
- Review details CETP's LBP-gene-family membership and the molecular basis of CETP-deficiency hyperalphalipoproteinemia (Biochim Biophys Acta 2000)
- Review highlights a paradox: CETP-inhibited rabbits show different atherogenicity than genetically CETP-deficient humans (Curr Opin Lipidol 2000)
- CETP activity falls in both growth hormone deficiency and acromegaly, tracking with IGF-1 and adrenal status (Atherosclerosis 2000)
- Phospholipid depletion shrinks reconstituted HDL from 9.2 to 8.0 nm and slows early cholesteryl ester transfer via CETP (J Lipid Res 2000)
- CETP B1B1 genotype predicts a larger cholesterol drop from switching to a low-saturated-fat diet, crossover trial finds (Atherosclerosis 2000)
- CETP concentration and transfer activity are normal in well-matched type 1 diabetics, contradicting earlier reports (Eur J Intern Med 2000)
- A review argues CETP-TaqI-B polymorphism data support genetic testing, while cautioning that CETP-inhibitor cardioprotection remains unproven (Clin Chem Lab Med 2000)
- Review makes CETP deficiency the central explanation for hyperalphalipoproteinemia and its paradoxical coronary risk (Atherosclerosis 2000)
- Review concludes CETP's atherogenic effect depends on metabolic background, proposing it as a therapeutic target in hyperlipidemia (Curr Opin Lipidol 2000)
- Prebeta1-HDL concentration tracks LDL-cholesterol independent of CETP mass (Clin Chim Acta 2000)
- Improving glycemic control lowers postprandial CETP activity and chylomicron particle numbers in type 2 diabetes (Atherosclerosis 2000)
- CETP variant R451Q lowers carotid artery thickness in men, while I405V harms only heavy drinkers (Eur J Clin Invest 2000)
- Blocking CETP-mediated cholesteryl ester transfer with an antibody makes LDL more resistant to oxidative modification (J Lipid Res 2000)
- CETP activity is lower in children and teens with insulin-dependent diabetes, alongside higher HDL cholesterol and apoA-I (Acta Paediatr 1999)
- Abdominal obesity blunts the HDL-raising benefit of the CETP B2 allele in men with insulin resistance features (Int J Obes 1999)
- Pravastatin lowers serum CETP 21% while probucol raises it 23%, with baseline CETP predicting Achilles tendon xanthoma regression (Atherosclerosis 1999)
- A 24-hour intravenous fat load leaves CETP activity unchanged acutely but raises it a week later (J Lipid Res 1999)
- CETP genotype, not insulin sensitivity, predicts how PLTP activity falls during hyperinsulinemia in men (J Lipid Res 1999)
- CETP accounts for 5% of small dense LDL variability in Chinese diabetic patients despite unchanged CETP activity (Atherosclerosis 1999)
- A review finds increased plasma CETP is atheroprotective in transgenic mice even with low but functional HDL, against prior assumptions (Atherosclerosis 1999)
- Probucol and bezafibrate change HDL-cholesterol in cholesterol-fed rabbits via CETP activity, not liver CETP mRNA (Jpn Circ J 1999)
- Dietary palmitic acid raises CETP activity and mass versus lauric and oleic acid diets, with opposite effects on PLTP (Atherosclerosis 1999)
- Two CETP variants jointly explain 12 percent of CETP activity variance in a European multi-country cohort, EARS study finds (Eur J Clin Invest 1999)
- Radiolabeled HDL cholesteryl ester lingers longer in rat plasma and clears more slowly from perfused liver after ex vivo CETP treatment (Proc Soc Exp Biol Med 1999)
- Adipose tissue CETP mRNA strongly correlates with plasma CETP levels and falls with age in coronary patients (Atherosclerosis 1998)
- Smoking lowers CETP activity and worsens postprandial HDL loss in normolipidemic men (J Lipid Res 1998)
- Desialylation of lipoproteins boosts CETP-mediated cholesteryl ester transfer from HDL while impairing reverse cholesterol transport (Atherosclerosis 1998)
- Simvastatin lowers plasma CETP only in Japanese patients with elevated baseline CETP levels (Clin Chem 1998)
- Probucol sustains elevated prebeta1-HDL in hypercholesterolemic patients while a low-cholesterol diet lowers it, tracking CETP mass change (Atherosclerosis 1998)
- A 28-residue peptide from hog plasma, related to apoC-III, inhibits CETP and clears 75 percent of plasma activity within an hour in vivo (Biochim Biophys Acta 1998)
- New CETP mutation R451Q raises CETP activity in men but lowers cholesterol in women, a sex-divergent effect (Atherosclerosis 1998)
- Oleic acid roughly doubles full-length CETP transcription in Caco-2 intestinal cells without affecting exon-9-deleted splice variant (Mol Cell Biochem 1997)
- A novel CETP nonsense mutation produces a paradoxical combination of very high HDL cholesterol and extreme post-meal triglyceride levels (Arterioscler Thromb Vasc Biol 1997)
- Acute hyperinsulinemia suppresses plasma CETP activity via a fall in free fatty acids, less so in NIDDM patients than healthy subjects (Metabolism 1997)
- LPL activity predicts HDL cholesterol only when CETP is present in mice, revealing a species-specific LPL-CETP interaction (J Lipid Res 1997)
- Exon-14 skipping explains why the common Japanese CETP splicing mutation produces essentially no detectable protein (Arterioscler Thromb Vasc Biol 1997)
- Cholestyramine lowers plasma CETP alongside LDL cholesterol, likely explaining its HDL-raising effect (Clin Pharmacol Ther 1997)
- ApoE-rich HDL is a better CETP substrate than apoA-II-containing HDL, three CETP-deficiency genotypes reveal (J Lipid Res 1997)
- Interferon alpha treatment for hepatitis C lowers CETP activity and mass alongside lipoprotein lipase and hepatic lipase (Hepatology 1997)
- Review surveys the molecular genetics of CETP deficiency and its still-controversial link to atherosclerosis (Curr Opin Lipidol 1997)
- Increased CETP activity tracks with the atherogenic lipoprotein profile of obese children (Atherosclerosis 1997)
- Cholesterol feeding raises rabbit CETP production 416% and plasma mass 230%, tracing CETP through fast and slow HDL-bound pools (Arterioscler Thromb Vasc Biol 1997)
- Non-smoking, alcohol-drinking men with the CETP V405 genotype may have up to 40 percent lower heart attack risk, Icelandic study suggests (Clin Genet 1997)
- Lipopolysaccharides alter both HDL and LDL size and charge while blocking CETP activity, one of three distinct inhibitory mechanisms identified (Biochim Biophys Acta 1996)
- Plasma triglyceride level, not dietary fat saturation, is the rate-limiting factor for CETP-mediated cholesteryl ester transfer in hypercholesterolemic women (Atherosclerosis 1996)
- CETP and PLTP push HDL particle size in opposite directions, and alcohol withdrawal reveals the effect in patients (J Biol Chem 1996)
- Vitamin E blocks 85% of the HCSF-diet-induced rise in hamster adipose CETP release and 70% of the plasma CETP activity increase (Atherosclerosis 1996)
- CETP gene variation explains one-fifth of the variability in plasma CETP levels, but not HDL cholesterol, family study finds (J Lipid Res 1996)
- SW872 liposarcoma cells offer a high-output model for studying cholesterol-driven CETP secretion (J Lipid Res 1996)
- ApoA-IV activates CETP lipid transfer as effectively as apoA-I, binding lipid emulsions with similar affinity (Biochim Biophys Acta 1996)
- CETP activity rises 20% postprandially in controls but falls in NIDDM patients, despite 35% higher fasting CETP activity in diabetics (Atherosclerosis 1996)
- A palmitic acid diet raises CETP activity 12 percent more than a stearic acid diet in young women (Metabolism 1996)
- Net cholesteryl ester transfer is elevated in hypertriglyceridemic hemodialysis patients, tracking triglyceride levels rather than renal status (Am J Nephrol 1996)
- CETP mediates the transfer of esterified oxysterols between lipoproteins, limiting their uptake into cells (J Lipid Res 1996)
- CETP activity exceeds that of adults and control children in kids on peritoneal dialysis for end-stage renal disease (Nephron 1996)
- Review weighs whether cholesterol redistribution by CETP is proatherogenic or a step in protective reverse cholesterol transport (Horm Res 1996)
- Review surveys the biochemistry and molecular basis of CETP deficiency disorders (J Atheroscler Thromb 1996)
- Gemfibrozil raises HDL3 cholesterol 34.5% and plasma CETP activity 15.8% in hypertriglyceridaemic patients (J Intern Med 1995)
- Plasma free fatty acids raise CETP mass and HDL-to-VLDL/LDL transfer but not LDL-to-HDL transfer, a directionally selective effect (Arterioscler Thromb Vasc Biol 1995)
- A fluorescence assay tracks CETP-mediated lipid transfer to equilibrium in under 30 minutes, supporting an adsorption-exchange-desorption-diffusion mechanism (Chem Phys Lipids 1995)
- Review questions whether CETP-mediated cholesterol transfer to apoB lipoproteins undermines the antiatherogenic label of reverse cholesterol transport (Atherosclerosis 1995)
- CETP mutation 442D:G is found in nearly a third of Japanese with very high HDL cholesterol, including the first documented case with atherosclerosis (Atherosclerosis 1995)
- Oleic acid, unlike linoleic acid, blocks the cholesterol-induced rise in CETP activity in hamsters (Atherosclerosis 1995)
- Liver-specific CETP transgenic mice show 30-40% lower HDL cholesterol and loss of the apoE-rich HDL1 subclass (Biochim Biophys Acta 1995)
- CETP TaqIB genotype distribution differs significantly between cholesterol gallstone patients and controls (J Lipid Res 1995)
- CETP deficiency yields abnormally large, cholesterol-rich apoA-I lipoprotein particles that bind but internalize poorly (Eur J Biochem 1995)
- A review synthesizes transgenic-mouse evidence that CETP links plasma triglyceride metabolism to low HDL cholesterol levels (Trends Cardiovasc Med 1995)
- Molecular genetics reveals CETP as both anti-atherogenic in human deficiency and pro-atherogenic when overexpressed in mice (J Intern Med 1995)
- Unesterified cholesterol up to 17 mol% speeds CETP-mediated lipid exchange without increasing CETP binding to the donor emulsion (Biochem J 1994)
- CETP mutations I14A and D442G together explain a graded rise in HDL cholesterol across 226 Japanese patients (J Clin Endocrinol Metab 1994)
- ApoA-II shields HDL from CETP-driven shrinkage by inhibiting hepatic lipase in transgenic mice (J Clin Invest 1994)
- CETP activity is lower in diabetic men without coronary disease than in disease-free non-diabetic men (Metabolism 1994)
- A review proposes CETP as the mechanistic switch converting protective HDL2 into atherogenic lipoproteins when triglyceride-rich particles accumulate (Atherosclerosis 1994)
- CETP TaqI B polymorphism predicts CETP activity and HDL cholesterol in non-smoking men, but alcohol and smoking alter the association (Atherosclerosis 1994)
- Antibody-mediated CETP inhibition raises HDL 30 to 40 percent and produces large apoE-rich HDL particles in hamsters, peaking at day 4 (J Lipid Res 1994)
- Dietary cholesterol raises plasma CETP activity in baboons regardless of dietary fat type (Metabolism 1994)
- CETP triggers dissociation of lipid-free apoA-I from HDL only when VLDL or LDL are also present (J Lipid Res 1994)
- Intraperitoneal insulin delivery raises CETP activity 25 percent independent of glucose control in type 1 diabetes (Metabolism 1994)
- ApoA-II binds CETP and shuts down its cholesteryl ester transfer activity while apoA-I and apoA-IV enhance it at low doses (J Lipid Res 1994)
- CETP activity is higher in IDDM patients with macroalbuminuria but does not correlate with HDL, HDL2, or HDL3 cholesterol (Diabetes Care 1994)
- LpA-I-associated CETP concentration is significantly higher in women than men, while hyperlipidemic men shift CETP toward LpA-I:A-II particles (J Lipid Res 1994)
- A bicycle marathon cuts CETP mass 29 percent and activity 14 percent while raising HDL cholesterol (Metabolism 1994)
- Fasting CETP levels rise only on the highest dietary cholesterol dose and track LDL cholesterol changes in young men (Arterioscler Thromb 1994)
- ApoAII enrichment of HDL3 acts as an uncompetitive inhibitor of CETP-mediated cholesteryl ester transfer (J Biol Chem 1994)
- LpA-I, not LpA-I:A-II, shows an inverse relationship with plasma CETP mass within the HDL3 density region (J Lipid Res 1994)
- CETP TaqI polymorphism predicts HDL cholesterol in Greek but not Italian migrants to Australia (Hum Biol 1994)
- Gemfibrozil raises HDL3 cholesterol 16% and CETP activity in NIDDM patients, alongside 14.7% and 18.8% rises in LPL and hepatic lipase (Atherosclerosis 1993)
- Pravastatin lowers LDL and raises apoA-I but leaves CETP levels and abnormal HDL subpopulation composition unchanged (Atherosclerosis 1993)
- A natural CETP inhibitor in selectively bred high-HDL baboons is identified as an N-terminal apoC-I fragment that binds apoA-I (J Lipid Res 1993)
- A CETP nonsense mutation at codon 309, detected via macrophage mRNA, is identified as a new cause of familial hyperalphalipoproteinemia (Biochem Biophys Res Commun 1993)
- CETP activity and mass rise in primary biliary cirrhosis, more so with hyperalphalipoproteinemia, correlating tightly with each other (r=0.90) (Hepatology 1993)
- Probucol raises plasma CETP 31% while paradoxically lowering adipose CETP mRNA, suggesting effects beyond local synthesis (J Lipid Res 1993)
- CETP activity is 26% lower in alcoholics, detecting 63% of cases at 82% specificity, but insufficient alone as an alcoholism marker (Alcohol Alcohol 1992)
- CETP and lipoprotein lipase together, not separately, shrink HDL particles via free fatty acid synergy (Biochim Biophys Acta 1992)
- Trans-elaidic acid increases CETP-mediated cholesteryl ester transfer while cis-oleic acid inhibits it at high concentration (Biochim Biophys Acta 1992)
- Homozygous and heterozygous CETP deficiency show graded shifts toward cholesteryl-ester-rich HDL and cholesteryl-ester-poor IDL that track with serum CETP level (Atherosclerosis 1991)
- Medium and long chain nonesterified fatty acids boost CETP-mediated cholesteryl ester transfer while short chains do not (Biochim Biophys Acta 1991)
- A monounsaturated-fat diet lowers CETP activity more than a polyunsaturated diet, paralleling LDL cholesterol reductions (Atherosclerosis 1991)
- CETP activity is 70% higher in smoking IDDM men than controls and 30% higher than nonsmoking IDDM men (Diabetes Care 1991)
- Copper-induced plasma oxidation frees CETP from HDL and shifts it onto LDL more sensitively than known oxidation markers (J Lipid Res 1991)
- Plasma CETP rises as an adaptive response to peripheral cholesterol flux and jumps further with probucol treatment (Clin Cardiol 1991)
- CETP TaqIB genotype tracks with HDL cholesterol at the population extremes, with the B2 allele enriched among high-HDL subjects (Clin Sci 1990)
- Sodium oleate disrupts the CETP-mediated LDL-HDL equilibrium, driving cholesteryl esters into a shrunken, lipid-depleted HDL fraction (Atherosclerosis 1990)
- ApoE-rich HDL that accumulates in CETP deficiency binds the LDL receptor with far higher affinity than LDL itself (J Clin Invest 1990)
- Hepatic lipase shrinks HDL particles only when VLDL and CETP are both present, and lipoprotein lipase blocks the effect (Atherosclerosis 1990)
- Plasma CETP levels vary nearly fourfold and correlate with apoA-I and apoE, with CETP concentrated in 129-154 kD HDL3/VHDL particles (J Clin Invest 1990)
- CETP locus DNA polymorphism acts as both a level gene for apoA-I and HDL cholesterol and a variability gene for LDL cholesterol (Acta Genet Med Gemellol 1990)
- A single-incubation isotopic assay simultaneously measures LCAT esterification and CETP-mediated cholesteryl ester transfer (Atherosclerosis 1990)
- Inhibiting CETP amplifies apoA-IV and apoE redistribution among lipoproteins during ex vivo plasma incubation (J Lipid Res 1989)
- A newly purified phospholipid transfer protein, LTP-II, lacks CETP cross-reactivity but boosts CETP-mediated cholesteryl ester transfer (J Lipid Res 1988)
- Review highlights CETP inhibition improving survival in a mouse model of sepsis (Curr Opin Lipidol 2026)
- Hepatic overexpression of the hepatokine Tsukushi impairs HDL-mediated reverse cholesterol transport in hamsters without changing CETP activity (J Lipid Res 2026)
- CETP shows the most consistent gene-diet interaction evidence of any lipid gene, especially with dietary fat composition (Curr Issues Mol Biol 2026)
- Higher CETP concentration is linked to coronary plaques in familial hypercholesterolemia, but not independently after adjustment (J Clin Lipidol 2026)
- Children with obesity show reduced CETP activity alongside broader HDL antioxidant breakdown and higher oxidative stress (J Clin Lipidol 2026)
- Largest paediatric lipid GWAS to date confirms CETP as a robust HDL locus in Indian schoolchildren, with rare CETP variants also implicated (J Hum Genet 2025)
- In Tangier disease, CETP activity drives an LDL-triglyceride buildup on top of near-total HDL loss, a four-patient case series shows (J Clin Endocrinol Metab 2025)
- CETP promoter and coding variants predict HDL cholesterol levels in a Bangladeshi population (Biochem Biophys Rep 2025)
- Tofacitinib raises CETP and atherogenic lipids in rheumatoid arthritis patients naive to prior biologic therapy (J Clin Lipidol 2025)
- Case report finds pemafibrate paradoxically lowers HDL cholesterol in a patient with CETP deficiency (J Clin Lipidol 2025)
- Meta-analysis of five early RCTs in 288 patients: obicetrapib reduces LDL-C by 41% and raises HDL-C by 157% (J Clin Lipidol 2025)
- CETP-driven HDL lowering, unlike ApoE knockout, does not worsen muscle wasting in dysferlin-deficient mice (Lipids Health Dis 2024)
- Review questions whether elevated HDL cholesterol truly protects against cardiovascular disease (J Clin Endocrinol Metab 2024)
- CETP gene variants help explain HDL cholesterol levels in children with sickle cell disease (Braz J Med Biol Res 2024)
- Bioinformatics and molecular docking identify the soy isoflavone genistein as binding CETP among three key HDL-raising natural-product targets (J Transl Med 2023)
- Traditional dietary pattern adherence modulates the CETP Taq1B link to triglyceride levels in angiography patients (Nutr J 2023)
- Small-quantity lipid-based nutrient supplements do not alter maternal HDL enzyme activity in pregnancy, but CETP and LCAT activity vary by season in Ghana (Curr Dev Nutr 2023)
- In a highly admixed population, four CETP gene variants explain part of the HDL-cholesterol variation across adolescents, adults and older adults (Clin Nutr ESPEN 2023)
- CETP is one of only three lipid-metabolism proteins strongly enriched in pre-beta-HDL, the small, highly active HDL subspecies (Basic Res Cardiol 2023)
- CETP is among seven cholesterol-handling genes up-regulated in peripheral blood of coronary artery disease patients (Curr Issues Mol Biol 2023)
- A review of HDL biology in atherosclerotic cardiovascular disease highlights the shift from HDL quantity to HDL quality, with attention to CETP inhibitor trial outcomes (Clin Investig Arterioscler 2023)
- The CETP rs708272 risk allele is linked to higher cardiac gene expression and interacts with diet and smoking to triple the risk of low HDL (Front Nutr 2023)
- Review notes that impaired apoC1 inhibition of CETP in diabetes may explain elevated CETP activity in diabetic patients (Cardiovasc Diabetol 2022)
- miR-16 simultaneously suppresses CETP alongside five other atherosclerosis-related genes in liver cells without toxicity (Sci Rep 2022)
- In two large Korean cohorts, whether CETP raises cholesterol with alcohol depends on a person's ALDH2 genotype (Sci Rep 2022)
- A mathematical model of triglyceride lipolysis explains why cholesterol acquisition by HDL is maximal at intermediate HDL concentrations (Metabolites 2022)
- CETP variant rs3764261 has a bigger population-level impact on low HDL cholesterol than smoking, Japanese cohort study finds (J Epidemiol 2022)
- Review of 49 studies finds the TaqIB CETP variant is the most widely studied gene-diet interaction affecting blood lipids (Curr Atheroscler Rep 2022)
- Exome study in an underrepresented Mexican cohort finds a novel CETP variant, rs11076176, linked to higher risk of low HDL cholesterol (Front Genet 2022)
- The CETP rs5883 T allele is linked to higher HDL cholesterol and lower risk of low HDL in postmenopausal obese women (Eur Rev Med Pharmacol Sci 2021)
- Human CETP transgene boosts macrophage reverse cholesterol transport in mice, but cannot rescue PLTP deficiency (J Physiol Biochem 2021)
- A high triglyceride to HDL cholesterol ratio predicts elevated CETP activity in children (Indian J Pediatr 2021)
- Obesity alters LCAT and CETP activities and shifts HDL toward smaller, less anti-oxidative particles in young women (Biomedicines 2021)
- Roux-en-Y gastric bypass lowers CETP activity alongside other markers of HDL function in severe obesity (Obes Surg 2020)
- A new ELISA for oxidized HDL finds the highest levels in patients with CETP-deficiency-related hyperalphalipoproteinemia, and lower levels with probucol treatment (J Atheroscler Thromb 2021)
- Fine-mapping in two Kuwaiti Arab cohorts flags rs1864163 in CETP as a candidate causal variant for HDL cholesterol (Hum Genet 2021)
- Swapping dietary palmitic acid for stearic acid raises CETP mass without changing its activity (Clin Nutr 2020)
- Apolipoprotein F emerges as a natural, LDL-selective inhibitor of CETP (Curr Opin Lipidol 2020)
- LDL receptor enables a CETP-independent route for macrophage cholesterol to reach faeces, mouse study finds (Circ Res 2020)
- CETP mass and activity vary only slightly across apoE- and apoC-III-defined HDL subtypes, while LCAT concentrates in apoE/apoC-III-free HDL (Lipids Health Dis 2020)
- Diet-controlled type 2 diabetes speeds catabolism of several HDL proteins, and CETP activity tracks inversely with plasma adiponectin (Biomolecules 2020)
- Red yeast rice supplement linked to extreme HDL cholesterol via apparent CETP downregulation in a case report (Lab Med 2020)
- Certain CETP gene haplotypes raise the triglyceride to HDL cholesterol ratio more often in Roma than Hungarian populations (Genes 2020)
- Korean GWAS discovers six novel CETP SNPs associated with low HDL cholesterol (PLoS One 2020)
- Book chapter reviews CETP research from its discovery to the disappointing clinical-trial era (Adv Exp Med Biol 2020)
- CETP variant rs6499861 lowers HDL cholesterol more strongly in obese Korean men and women with a family history of diabetes (J Lipid Atheroscler 2019)
- CETP Taq1B genotype shifts HDL and LDL subclass distribution in African-American men (Future Cardiol 2019)
- High-dose PFOA raises HDL cholesterol by suppressing cholesteryl ester transfer activity in mice (Toxicol Sci 2019)
- Fish intake and dietary fat modify how two CETP gene variants affect cholesterol and triglyceride changes over time (Eur J Clin Nutr 2019)
- Kiwifruit raises adipose CETP gene expression but not serum CETP activity in hamsters (Avicenna J Phytomed 2019)
- CETP rs708272 raises HDL cholesterol and lowers atherogenic index in men but not women, without affecting coronary disease risk (Medicine 2018)
- Dietary fat intake modifies how CETP variant rs5882 affects HDL cholesterol and blood pressure risk (Iran J Basic Med Sci 2018)
- CETP markers show strong associations with HDL cholesterol across obesity phenotypes in an Iranian cohort, unlike most FTO variants (Eat Weight Disord 2020)
- Prebeta-1 HDL, the particle CETP feeds on, is elevated across three dyslipidaemia phenotypes in 2,435 people (J Clin Lipidol 2018)
- Exercise raises HDL in CETP-transgenic mice by lowering CETP activity 19%, and an anabolic steroid specifically blunts that effect (Lipids 2017)
- Human CETP transgenic pigs created as a new model for dyslipidaemia and atherosclerosis research (Lipids Health Dis 2017)
- Nat Rev Cardiol: most genetic variants that raise HDL-C don't lower cardiovascular risk, but CETP variants are a notable exception (Nat Rev Cardiol 2018)
- Neovascular age-related macular degeneration is linked to more HDL and IDL particles, an association unaffected by the CETP D442G mutation (J Lipid Res 2017)
- CETP variant rs3764261 is one of four risk alleles linked to lower HDL cholesterol in pregnant Chinese women (Oncotarget 2017)
- The SGLT2 inhibitor dapagliflozin lowers HbA1c and body weight in type 2 diabetes but leaves HDL cholesterol, subfractions, and CETP activity unchanged (Cardiovasc Diabetol 2017)
- Policosanol supplementation reduced CETP activity by up to 32% and lowered blood pressure in healthy adults (Int J Mol Med 2017)
- Meta-analysis links the CETP C-629A polymorphism to higher coronary heart disease risk and circulating CETP in Caucasians (Oncotarget 2017)
- A review traces the evolution of HDL-raising therapeutics from niacin and fibrates to CETP inhibitors, reconstituted HDL, and apoA-I mimetics (Curr Pharm Des 2017)
- Systematic review of 23 studies finds the CETP B1 risk allele responds better to dietary interventions than B2B2 (Nutr Metab 2017)
- CETP variant rs1800775 is associated with HDL cholesterol and total cholesterol, but not LDL, in pregnant Chinese women (J Clin Lipidol 2017)
- CETP-overexpressing transgenic rabbits show more macrophage foam cells despite unchanged lesion area (Mediators Inflamm 2017)
- Kinetic tracer studies reveal CETP inhibition raises apoA-I and lowers apoB by shifting catabolism rates of HDL and LDL in opposite directions (Curr Opin Lipidol 2016)
- Plasma CETP is higher in metabolic syndrome, but the Taq1B genotype itself shows no direct link to the syndrome in Iranian subjects (Biochem Genet 2016)
- CETP I405V shows no link to age or cardiovascular disease despite raising HDL cholesterol (BMC Geriatr 2016)
- CETP TaqIB, but not apo AI 75G/A, significantly shapes HDL cholesterol levels in Polish men and women (Arch Med Sci 2016)
- Higher serum CETP levels and the -629A allele are linked to angiographically confirmed coronary atherosclerosis (Indian J Clin Biochem 2017)
- Review distinguishes humanized-mouse from rabbit models to find where CETP inhibition truly protects against atherosclerosis (Eur J Clin Invest 2016)
- Six months of aerobic exercise raises oxidized-HDL levels in women without any change in CETP or adiponectin concentration (Free Radic Res 2016)
- Review weighs past CETP inhibitor trial failures against hopes for newer, more favourable agents (Clin Med Insights Cardiol 2016)
- Eight CETP gene polymorphisms show distinct HDL, LDL, and triglyceride associations in Kazak and Uyghur adults from Western China (Int J Environ Res Public Health 2015)
- Review argues CETP inhibitors remain the most potent HDL-raising agents but their cardiovascular benefit is still unproven (Clin Ther 2015)
- Niacin/laropiprant lowers CETP activity alongside multiple inflammatory markers but modestly improves HDL efflux without changing HDL antioxidant capacity (J Am Heart Assoc 2015)
- Novel CETP microdeletion lowers enzyme activity and raises HDL-associated cholesterol in three carriers (Clin Genet 2016)
- CETP variant rs708272 is one of three protective polymorphisms shielding HIV patients on antiretroviral therapy from atherogenic dyslipidemia (AIDS Res Hum Retroviruses 2015)
- A review proposes that HDL regulates the beta2-adrenergic receptor pathway through the same ADCY9 signaling axis linked to dalcetrapib response (Arch Med Res 2015)
- Meta-analysis finds LDL-C and non-HDL-C, not HDL-C, predict lesion reduction across CETP-expressing animal and human trials (Eur J Pharmacol 2015)
- Meta-regression of 167 311 patients finds raising HDL cholesterol with CETP inhibitors does not predict clinical benefit (Heart 2015)
- Review proposes historic hepatic schistosomiasis as a screening factor behind East Asia's unusually high rate of genetic CETP deficiency (Nutrients 2015)
- The CETP locus is one of only three individually significant lipid-associated SNPs confirmed in a first Algerian population genetics study (Int J Clin Exp Pathol 2015)
- A review shows PON1 activation and its flux across HDL particle sizes during maturation are blocked by CETP and LCAT inhibitors (Clin Chim Acta 2015)
- CETP variants A373P and Taq1 have opposite effects on low HDL cholesterol risk in Iranian children and teenagers (Atherosclerosis 2014)
- Review argues HDL-raising therapy remains an unmet cardiovascular need after torcetrapib and dalcetrapib failures (Transl Med UniSa 2015)
- CETP TaqIB B2B2 genotype is linked to more favorable HDL cholesterol levels in West Siberian Caucasians (Bull Exp Biol Med 2014)
- CETP I405V Val/Val genotype significantly determines HDL cholesterol levels in myocardial infarction patients (J Clin Diagn Res 2014)
- A review names failed CETP-inhibitor and niacin trials as key evidence complicating the HDL-cholesterol paradigm for cardiovascular prevention (Clin Pharmacol Ther 2014)
- A review names CETP mutations as a specific genetic cause of high HDL cholesterol, distinct from the mutations that cause low HDL (Curr Med Chem 2014)
- CETP TaqIB mutation carriers with low HDL cholesterol have a fivefold higher risk of premature coronary artery disease in Egyptians (J Clin Lipidol 2014)
- Review names CETP inhibition among the most promising pharmacological approaches to raising HDL despite recent trial failures (Curr Opin Lipidol 2013)
- CETP variant rs708272 lowers coronary atherosclerosis risk while a linked variant shapes HDL cholesterol in Chinese healthy controls (Lipids Health Dis 2013)
- A review names CETP inhibition among three specific pharmacological strategies to boost reverse cholesterol transport (Indian J Exp Biol 2013)
- A Filipino GWAS finds suggestive CETP and TOM1 associations with HDL cholesterol and allelic heterogeneity at the CETP locus (J Lipid Res 2013)
- HIV infection is associated with elevated plasma CETP and LCAT alongside low HDL, without one-year progression of subclinical atherosclerosis (Atherosclerosis 2013)
- CETP rs3764261 T allele is the top single-locus HDL-C predictor among 13 SNPs in a 3,050-person Japanese cohort (PLoS One 2013)
- Review surveys torcetrapib, dalcetrapib, anacetrapib, and evacetrapib as HDL-raising targets after the mortality signal in ILLUMINATE (Curr Vasc Pharmacol 2012)
- CETP I405V is linked to lower small dense LDL levels, unrelated to coronary artery disease risk, in Indian subjects (Indian J Clin Biochem 2012)
- CETP is the least frequently mutated of three genes (LIPG, CETP, GALNT2) found in Caucasian families with extremely high HDL cholesterol (PLoS One 2012)
- Unlike LCAT or ABCA1 mutations, heterozygous CETP mutations leave plasma sphingosine-1-phosphate and apoM levels unaffected (Atherosclerosis 2011)
- The PAGE study fails to replicate CETP rs1864163's HDL-C association across roughly 38,000 diverse-ancestry adults despite adequate power (PLoS Genet 2011)
- CETP expression partly rescues abnormal HDL distribution but not atherosclerosis in SR-BI-deficient mice (J Biol Chem 2011)
- Dense candidate-gene genotyping confirms CETP among established HDL-C loci in a 7,857-person meta-analysis and reveals multiple independent signals at several loci (Circ Cardiovasc Genet 2011)
- Three CETP variants are among only six SNPs linked to HDL cholesterol in European adolescents, first shown in this age group (Atherosclerosis 2011)
- A review classifies novel HDL-raising drugs into four strategies, including CETP inhibition, to address residual cardiovascular risk (Nat Rev Cardiol 2011)
- Higher CETP levels in follicular fluid correlate with more mature oocytes and higher IVF/ICSI fertilization rates (Iran J Reprod Med 2011)
- Review argues lipid therapy must look beyond LDL, citing CETP inhibition as promising but still unproven in outcome trials (Curr Pharm Des 2011)
- An orally delivered trefoil-factor-CETP chimeric vaccine raises intestinal and serum anti-CETP antibodies and inhibits atherosclerosis in rabbits (Peptides 2010)
- CETP variant rs5882 is the second-strongest of nine genetic hits for low HDL cholesterol and heart disease risk in a 60-gene screen (J Lipid Res 2010)
- CETP Taq1B B2B2 genotype is linked to the highest HDL cholesterol and lowest oxidative stress marker levels in Tehran adults (Lipids Health Dis 2010)
- Octodon degus develop human-like atherosclerosis on a cholesterol diet, with baseline CETP activity comparable to humans (Atherosclerosis 2010)
- CETP is one of only four genes confirmed to affect HDL cholesterol, with no evidence its effect depends on alcohol intake (Atherosclerosis 2010)
- A review identifies CETP as a key enzyme liberating serum amyloid A during acute-phase HDL remodeling (Curr Opin Endocrinol Diabetes Obes 2010)
- A review argues that after the torcetrapib failure, HDL functionality biomarkers are needed since HDL cholesterol alone is not a functional measure (Expert Rev Cardiovasc Ther 2010)
- CETP TaqIB genotype distinguishes a longevity syndrome of simultaneously high HDL and LDL cholesterol (Open Cardiovasc Med J 2010)
- A review argues that the harms of torcetrapib trace to its own tight CETP binding and an aldosterone-like effect, not to CETP inhibition itself (Rom J Intern Med 2010)
- Combined LIPC and CETP I405V variants double coronary artery disease risk, but the effect fades in women with high HDL cholesterol (Genet Test Mol Biomarkers 2009)
- Nevirapine raises HDL cholesterol in HIV patients by boosting apoA-I production, with a modest CETP activity increase (Arterioscler Thromb Vasc Biol 2009)
- LCAT overexpression raises HDL cholesterol but does not boost macrophage reverse cholesterol transport, even alongside SR-BI or CETP coexpression (Circulation 2009)
- CETP TaqIB significantly shapes baseline HDL subpopulation profile in postmenopausal women, though hormone therapy response is largely unaffected (Clin Endocrinol 2010)
- CETP genotype tracks with HDL cholesterol and triglycerides but not with coronary artery disease risk in Turkish angiography patients (Eurasian J Med 2009)
- CETP -629C/A AA genotype raises HDL cholesterol but may still carry higher coronary artery disease risk in Iranian Azeris (Iran Biomed J 2009)
- CETP-HDL association is one of only four gene-lipid-trait pairs replicated using a new cardiovascular gene chip in a multiethnic cohort (J Lipid Res 2009)
- CETP I405V VV genotype is linked to higher HDL cholesterol in Turks, an effect modified by sex and triglycerides (Cell Biochem Funct 2009)
- CETP variant A373P is independently linked to lower HDL cholesterol and ApoA-I-containing lipoproteins, largely independent of other tested genes (Metabolism 2009)
- CETP activity is markedly elevated in Iranian patients with primary combined hyperlipidaemia, modulated by Taq1B genotype (Indian J Med Res 2009)
- CETP I405V V-allele carriers lose more ApoA-I and HDL cholesterol when switched from a high to low polyunsaturated fat diet (Horm Metab Res 2009)
- A review weighs four possible explanations for why torcetrapib raised cardiovascular risk despite raising HDL cholesterol (Ann Med 2009)
- A review links the B1B1 CETP genotype to higher CETP activity, lower HDL cholesterol, and more pronounced postprandial lipemia (Curr Med Chem 2009)
- A review argues the off-target effects of torcetrapib, not the CETP-inhibition mechanism itself, likely overrode any cardiovascular benefit (Cardiol Clin 2008)
- CETP Taq1B B2 allele cuts coronary stenosis risk by 18 percent overall, and 38 percent in male nonsmokers, in Tunisians (Arch Cardiovasc Dis 2008)
- JTT-705 (dalcetrapib) raised HDL-C 26% and improved endothelial function only in low-baseline-HDL patients (Thromb Res 2009)
- Two CETP variants are among only seven SNPs confirmed to affect HDL cholesterol in a 384-SNP, 251-gene screen (J Lipid Res 2008)
- Review attributes statins' modest HDL-raising effect to reduced CETP-mediated cholesterol flow (Cardiovasc Drugs Ther 2008)
- Neither high CETP activity nor low HDL cholesterol predicts cardiovascular events in stage V chronic kidney disease (Nephrol Dial Transplant 2008)
- Six weeks of endurance training lowers CETP activity regardless of egg intake in unfit adults (J Nutr Biochem 2008)
- Review reconsiders the protective reputation of HDL after the abrupt ILLUMINATE failure of torcetrapib (Biochem Pharmacol 2008)
- A review argues ABCA1 and ABCG1 transporters, not raw HDL cholesterol level, drive HDL's atheroprotective effect after the torcetrapib failure (Cell Metab 2008)
- A review concludes the mineralocorticoid-driven hypertension seen with torcetrapib is not a CETP-inhibitor class effect, since JTT-705 and MK-825 do not raise blood pressure (Nat Clin Pract Cardiovasc Med 2008)
- LTIP loses its CETP-inhibiting activity when sequestered into a 470 kDa apolipoprotein complex (J Lipid Res 2008)
- Probucol lowers ANGPTL3 and large-HDL phospholipids while raising prebeta1-HDL in hypercholesterolemic patients (Atherosclerosis 2008)
- CETP gene is the only lipid-metabolism gene whose HDL-C association shifts with menopause in the ARIC Study (Atherosclerosis 2008)
- CETP B1B1 genotype is nearly twice as common in Taiwanese people with a parental history of cardiovascular disease (Med Princ Pract 2008)
- A review argues four disappointing torcetrapib trials require refining the HDL hypothesis, since HDL may be more carrier protein than cholesterol transporter (Ann Med 2008)
- A review questions whether CETP inhibitors can ultimately reduce cardiovascular events after torcetrapib raised blood pressure without slowing coronary atherosclerosis (Am J Cardiol 2007)
- CETP activity is significantly elevated in Iranian patients with primary hypertriglyceridemia, and modulated by Taq1B genotype (Pak J Biol Sci 2007)
- A review of CETP inhibition in dyslipidemia finds that the benefit of raising HDL depends heavily on triglyceride-rich lipoprotein levels (Curr Atheroscler Rep 2007)
- Fenofibrate shifts HDL from large HDL2 to small HDL3 particles over 5 years in type 2 diabetes without changing CETP, PLTP, or LCAT activity (Diabetologia 2007)
- CETP -629C>A genotype effect on HDL cholesterol is only partly explained by its impact on cholesteryl ester transfer activity (Scand J Clin Lab Invest 2008)
- CETP variants replicate their known HDL cholesterol association in renal transplant patients, but do not predict fluvastatin response (J Lipid Res 2007)
- Review dissects how CETP and PLTP jointly drive low HDL in type 2 diabetes via specific apolipoprotein modulators (Curr Opin Lipidol 2007)
- Psyllium plus plant sterols lowers CETP activity by 11% and raises LDL receptor abundance by 26%, explaining part of its LDL-lowering mechanism (J Nutr 2007)
- A meta-analysis of 23 trials finds HDL-raising tracks with reduced atherosclerosis progression for every drug class except the torcetrapib-atorvastatin combination (J Clin Lipidol 2007)
- A review classifies CETP among the HDL-elevating drug targets, distinct from ApoA1-mimetic fast-acting approaches, for treating atherosclerosis (Cardiovasc Hematol Agents Med Chem 2007)
- Serum CETP correlates positively with total cholesterol, beta-lipoprotein, apoB, and apoE, and is lower overall but higher in women, in type 2 diabetes (Med Princ Pract 2007)
- Review of thirteen clinical CETP-inhibition studies finds pharmacological inhibitors raise HDL-C more consistently than vaccines (Curr Med Res Opin 2006)
- Plasma CETP mass and PLTP activity, but not adiponectin or resistin, are independently linked to leptin levels in type 2 diabetes (Biochim Biophys Acta 2007)
- A review previews a large-scale CETP-inhibitor imaging and outcomes program as the next frontier after statin-driven atherosclerosis regression (Can J Cardiol 2006)
- Torcetrapib can double HDL cholesterol while lowering LDL cholesterol by up to 42 percent, a review of CETP inhibitors reports (Curr Opin Pharmacol 2006)
- Review attributes chronic renal failure's HDL disorders partly to elevated CETP activity (Am J Physiol Renal Physiol 2006)
- Doubling torcetrapib to its maximum tolerated dose more than doubles HDL cholesterol when combined with atorvastatin (Drugs Today 2006)
- Review dissects biochemical pathways beyond HDL-C by which CETP inhibition might protect against atherosclerosis (Arterioscler Thromb Vasc Biol 2006)
- A review traces the CETP-inhibitor rationale from CETP-deficient Japanese populations with high HDL to early human trials of torcetrapib and JTT-705 (J Am Coll Cardiol 2006)
- A review finds genetic and plasma CETP-level studies give no clear answer on whether CETP inhibition will reduce atherosclerosis risk (Curr Drug Targets Cardiovasc Haematol Disord 2005)
- ApoCI blocks CETP by disrupting CETP-HDL binding through its electrostatic C-terminal helix (J Biol Chem 2005)
- A review of torcetrapib/atorvastatin combination therapy covers the chemistry, mechanism, and pharmacokinetics behind their complementary lipid effects (Expert Rev Cardiovasc Ther 2005)
- ABCG1's discovery as a large-HDL cholesterol exporter suggests CETP inhibition may enhance, not reduce, cholesterol efflux (Curr Opin Lipidol 2005)
- Familial low HDL patients have markedly reduced prebeta-HDL alongside elevated CETP and hepatic lipase activity, unrelated to prebeta-HDL levels (J Lipid Res 2005)
- Clinician update reviews how CETP inhibition raises HDL by 50 to 100 percent in humans but flags mixed results across metabolic contexts (Circulation 2005)
- Review names CETP inhibition as an emerging strategy for HDL-targeted cardiovascular drug development (Nat Rev Drug Discov 2005)
- CETP transgenic rats show dramatic lipid shifts on a sucrose diet but not on a high-fat/high-cholesterol diet (Atherosclerosis 2005)
- Prospective cohort data link elevated CETP concentration to higher cardiovascular risk only when triglycerides are also high (Curr Opin Lipidol 2004)
- Postprandial triglyceride-rich lipoproteins boost CETP-mediated cholesteryl ester transfer from LDL and HDL regardless of dietary fat type (Am J Clin Nutr 2004)
- Review names CETP inhibition as one of the two most important new targets for raising HDL cholesterol (Neth Heart J 2004)
- Review surveys CETP as a pivotal HDL-raising drug target as human CETP inhibitor data become available (J Lipid Res 2004)
- JTT-705 reshapes HDL toward larger, apolipoprotein E-rich particles with more antioxidant enzyme activity in rabbits (Arterioscler Thromb Vasc Biol 2004)
- The CETP-to-LCAT activity ratio, not either enzyme individually, predicts small HDL3 particle enrichment in healthy Mexican adults (Endocr Res 2004)
- Daily exercise raises HDL cholesterol most in men with the CETP B1B1 genotype (Clin Genet 2004)
- JTT-705 raises HDL cholesterol in rabbits by speeding up apolipoprotein A-I synthesis, not by slowing its breakdown (Atherosclerosis 2004)
- Review reports CETP autoimmunization vaccine has reached human trials alongside apolipoprotein mimetics (Curr Atheroscler Rep 2004)
- Review positions CETP as a new therapeutic target, noting statins and fibrates already attenuate its activity indirectly (Pharmacol Ther 2004)
- Review examines conflicting evidence on CETP genetic variation and longevity in centenarians (J Atheroscler Thromb 2004)
- CETP activity rises 50% in one ABCA1-heterozygote kindred but not three others, alongside severe HDL abnormalities (Atherosclerosis 2003)
- Review proposes CETP-driven cholesteryl ester transfer as the metabolic link between high triglycerides and low HDL cholesterol in insulin resistance (Eur J Clin Invest 2003)
- CETP TaqI B polymorphism only modestly raises HDL cholesterol in Saudis, too small an effect to explain their low HDL levels (Clin Sci 2003)
- Treating periodontitis raises HDL cholesterol by 10.7% and CETP activity by 19.4%, improving cholesterol efflux especially in patients whose CRP fell (J Lipid Res 2004)
- Early phase I and II data show CETP inhibitors raise HDL-C by up to 70 percent, though effects on triglycerides remain unclear (Curr Opin Investig Drugs 2003)
- CETP activity rises 32% after a fatty meal, but neither CETP nor PLTP activity correlates with the postprandial rise in plasma cholesterol efflux capacity (Nutr Metab Cardiovasc Dis 2003)
- Review argues the time is right to test CETP inhibition in randomized human atherosclerosis trials (Arterioscler Thromb Vasc Biol 2003)
- Tibolone lowers HDL cholesterol by 14% via increased hepatic lipase activity, but preserves cholesterol efflux capacity without affecting CETP activity (Clin Endocrinol 2003)
- Overexpressing phospholipid transfer protein raises VLDL secretion 1.5-fold while lowering HDL cholesterol and CETP activity in CETP-transgenic mice (J Lipid Res 2002)
- Atorvastatin cuts postprandial CETP-mediated cholesteryl ester transfer from HDL to chylomicrons by up to 26% (J Clin Endocrinol Metab 2002)
- Antioxidant vitamins blunt the protective HDL2 rise from simvastatin-niacin therapy, possibly by stimulating CETP activity, a review concludes (Arterioscler Thromb Vasc Biol 2002)
- A review reports that apolipoprotein A-II modulates HDL atherogenicity in opposing directions, inhibiting CETP activity as one of several intermediate effects on reverse cholesterol transport (Atherosclerosis 2002)
- CETP mass varies widely in healthy Japanese people with very high HDL cholesterol (Intern Med 2002)
- HDL from rabbits treated with JTT-705 removes cholesterol from macrophages just as efficiently as normal HDL, despite higher CETP-inhibited levels (Atherosclerosis 2002)
- CETP levels are elevated in Chinese heart attack and stroke patients, while CETP-deficient carriers show a favorable lipid profile despite low CETP mass (Chin Med J 2002)
- CETP TaqI B2 allele raises HDL cholesterol more strongly in men than women in a rural Japanese population (J Epidemiol 2002)
- CETP TaqIB B2B2 genotype protects against atherosclerosis only when it actually lowers CETP mass, angiography-based Japanese study finds (Atherosclerosis 2001)
- CETP TaqIB does not predict angiographically documented coronary artery disease risk, large case-control study finds (Clin Genet 2001)
- Lipid transfer inhibitor protein rises 3-fold in hypercholesterolemia independent of CETP levels themselves (Arterioscler Thromb Vasc Biol 2001)
- HDL cholesteryl esters still reach LDL in ponies despite their total lack of CETP activity (Comp Biochem Physiol B Biochem Mol Biol 2001)
- A review identifies apolipoprotein C-I as the major plasma inhibitor of CETP, one of several ways C-I and C-III modulate lipoprotein metabolism (Curr Opin Lipidol 2001)
- A review finds PLTP, not CETP, is the main driver shaping HDL size and composition via phospholipid transfer and HDL conversion (Atherosclerosis 2001)
- Review traces how CETP deficiency reshapes HDL and LDL and raises coronary risk despite higher HDL-cholesterol (Front Biosci 2001)
- Different dietary fatty acids produce distinct postprandial CETP activity responses in healthy young men (Am J Clin Nutr 2001)
- A lower CETP B2 allele frequency in Valencia may help explain the unexpectedly high heart disease rate in the region (Atherosclerosis 2000)
- Probucol raises CETP and LCAT activity despite lowering HDL, reframing its HDL reduction as pro-transport rather than atherogenic (Atherosclerosis 2000)
- A review names CETP, apoA-II, and hepatic lipase as prime targets for pharmacologic inhibition among new HDL-directed atherosclerosis therapies (Curr Atheroscler Rep 2000)
- Hypertriglyceridemia with low HDL cholesterol raises CETP activity and impairs cellular cholesterol efflux capacity in men (Atherosclerosis 2000)
- Apolipoprotein L levels rise in primary CETP deficiency and correlate with triglycerides across hyperlipidemic and diabetic subjects (J Lipid Res 2000)
- CETP mass and activity rise significantly after a meal, with the Taq 1B polymorphism predicting who has the lowest levels (Br J Nutr 2000)
- CETP TaqIB genotype explains major HDL cholesterol differences in renal transplant patients, but only in those without abdominal obesity (Nephron 2000)
- CETP rises over time regardless of whether progestogen is added to low-dose estradiol in diabetic women (Diabet Med 2000)
- Insulin lowers CETP activity 9.5% in healthy adults but not in type 2 diabetes, while PLTP responds to both insulin and Acipimox in both groups (Diabetes 1999)
- A new sandwich ELISA measures plasma CETP concentration with under 10% assay variability (Clin Biochem 1999)
- Testosterone suppression by cetrorelix raises apoA-I, insulin, and leptin, with only small CETP and hepatic lipase decreases in pooled analysis (Exp Clin Endocrinol Diabetes 1999)
- A review asks whether CETP is beneficial or harmful, weighing evidence for both proatherogenic and antiatherogenic roles (Crit Rev Clin Lab Sci 1998)
- CETP activity rises in hyperthyroidism and falls in hypothyroidism, tracking free T4, though hepatic lipase drives the HDL2 changes (J Clin Endocrinol Metab 1998)
- CETP mutation G1533A raises transfer activity and lowers HDL cholesterol, tested with a new simplified assay (Clin Chem Lab Med 1998)
- Smoking cuts lipoprotein lipase and LCAT activity but leaves CETP activity unchanged, though CETP still tracks HDL3 in non-smokers (Eur J Clin Invest 1998)
- CETP-driven cholesterol enrichment of remnant particles worsens atherosclerosis risk in diabetic dyslipidaemia (Eur Heart J 1998)
- A rare CETP intron 14 mutation, usually found only in Japanese, is identified in a Finnish family with high HDL cholesterol (Arterioscler Thromb Vasc Biol 1998)
- A new simple sandwich immunoassay for CETP mass correctly detects genetic CETP deficiency in human serum (Clin Chim Acta 1998)
- An overview of reverse cholesterol transport shows CETP pulling in the opposite direction from apoA-I (Eur Heart J 1998)
- PLTP shares the same optimal HDL surface charge as CETP, showing both lipid transfer proteins are governed by electrostatics (J Lipid Res 1998)
- HDL and VLDL levels, not CETP activity, determine the direction of cholesteryl ester transfer in alcohol abusers (Arterioscler Thromb Vasc Biol 1997)
- A direct LDL isolation technique offers a simpler alternative for measuring CETP activity (Clin Chim Acta 1997)
- CETP shares seven lipid-binding helical arrays with apoA-I, apoA-II, apoC-I/II/III, and apoE despite a smaller active surface (Mol Cell Biochem 1997)
- Review contrasts how CETP and PLTP remodel HDL size distribution through distinct mechanisms (Trends Cardiovasc Med 1997)
- A CETP mutation previously reported only once is surprisingly common in North Americans with high HDL cholesterol (Clin Biochem 1997)
- Species already low in CETP and high in lipoprotein lipase respond most to NO-1886, a compound that raises HDL cholesterol without touching CETP activity (Metabolism 1997)
- A newly found CETP 3-prime-UTR variant lowers CETP activity by nearly 30 percent, replicated in two independent samples (Atherosclerosis 1996)
- Free fatty acids fluidize the lipoprotein surface, offering a physical explanation for how they modulate CETP activity (Eur J Biochem 1996)
- CETP activity rises in the second trimester of pregnancy alongside falling hepatic lipase and rising estradiol (J Lipid Res 1996)
- Plasma triglycerides, not LCAT or CETP concentration, drive cholesterol esterification and HDL remodeling (ATVB 1995)
- A Tall-lab review reconciles CETP deficiency and CETP overexpression both showing antiatherogenic signals, via its role in reverse cholesterol transport (Curr Opin Lipidol 1995)
- Smoking lowers and drinking raises HDL2-C and HDL3-C in healthy men, but neither affects CETP or LCAT activity (Jpn Circ J 1995)
- A new immunoassay measuring CETP activity via radiolabeled cholesteryl ester transfer matches the ultracentrifugation method with r=0.94, without separating donor and acceptor lipoproteins (Clin Chem 1995)
- CETP deficiency enlarges apoA-I lipoprotein particles and impairs their cholesterol-handling function (J Lipid Res 1995)
- Antibody-mediated CETP inhibition in hamsters produces apoE-rich, apoA-I-poor HDL particles that revert toward baseline within two weeks (Lipids 1995)
- CETP and LCAT activity rise postprandially in NIDDM, but neither differs from controls at baseline (Atherosclerosis 1995)
- Dietary cholesterol raises both LDL and HDL cholesterol in young women without changing fasting plasma CETP levels (Arterioscler Thromb Vasc Biol 1995)
- CETP shrinks reconstituted HDL from 9.2 to 8.0 nm by swapping cholesteryl ester for triglyceride and losing an apoA-I molecule (J Biol Chem 1995)
- CETP and LCAT localize mainly to LpA-I, not LpA-I:A-II, particles, a review finds, explaining why LpA-I promotes more cholesterol efflux (Atherosclerosis 1994)
- CETP mRNA sequences are detected in ovary, lung, intestine, and heart tissue, not just liver, suggesting a locally active membrane-bound CETP form (Biochem Biophys Res Commun 1994)
- Enlarged HDL2 from CETP-deficient patients fails to protect macrophages from cholesterol accumulation (J Biochem 1994)
- A review identifies probucol as the sole drug shown to stimulate CETP activity and boost reverse cholesterol transport (Pharmacol Ther 1994)
- Heart transplant recipients' paradoxically high HDL traces to partial CETP and hepatic lipase deficiency (Atherosclerosis 1993)
- Intron 14 CETP splicing defect is found in 3.5% of Japanese patients with marked hyperalphalipoproteinemia and an estimated 1/42,000 homozygote frequency (Atherosclerosis 1993)
- A rapid NdeI-based PCR screen finds the intron 14 CETP splicing defect in 21 of 121 Japanese patients with hyperalphalipoproteinemia (Hum Genet 1993)
- CETP reshapes HDL3 differently depending on whether particles carry apoA-II alongside apoA-I (Biochim Biophys Acta 1992)
- A review by Alan Tall names CETP and hepatic lipase as key genetic determinants of HDL catabolism, with lipoprotein lipase driving HDL formation (J Intern Med 1992)
- CETP and PLTP occupy different HDL-sized macromolecular complexes across four vertebrate species (Atherosclerosis 1991)
- A review credits probucol as the only drug shown to directly raise CETP activity and mass, potentially aiding cholesterol removal from tissues (Atherosclerosis 1991)
- CETP and apoA-I gene polymorphisms show no association with coronary heart disease in a Sri Lankan population, though the CETP B1 allele tracks with lower HDL cholesterol (Atherosclerosis 1990)
- Impaired cholesteryl ester transfer to the HDL3 pool is linked to vascular disease across several hyperlipidemic disorders (Atherosclerosis 1989)
- A minor pre-beta lipoprotein containing apoD, LCAT, and CETP channels newly esterified cell cholesterol into HDL (J Biol Chem 1989)
- Stripping cholesteryl arachidonate from HDL via CETP-mediated transfer reduces its ability to trigger endothelial prostacyclin release (J Lipid Res 1985)
- Indian patients with high HDL cholesterol are more active, leaner, and at lower cardiovascular risk, with numerically but not significantly lower CETP levels (Ir J Med Sci 2025)
- The CETP rs708272 AA genotype is linked to higher HDL cholesterol in an Iranian coronary artery disease cohort (J Clin Lab Anal 2024)
- Review links HDL dysfunction in type 2 diabetes to impaired glycaemic control and highlights CETP inhibitors as a candidate therapy (Curr Med Chem 2024)
- A methodology review highlights the APOE*3-Leiden.CETP mouse as a model that closely mimics human lipoprotein metabolism (Vasc Biol 2024)
- Dietary antioxidant intake does not interact with the CETP Taq1B polymorphism to affect lipid profile or coronary stenosis severity (Food Sci Nutr 2024)
- Cholesterol efflux capacity, but not CETP-mediated cholesterol ester transfer, correlates inversely with peripheral plaque volume (Biomedicines 2023)
- Targeted sequencing finds low-HDL-linked variants in CETP and three other genes in one in six people with metabolic syndrome (Diabetol Metab Syndr 2022)
- CETP activity correlates with atherogenic VLDL levels in women with anorexia nervosa (Biomedicines 2022)
- Eating up to two eggs daily downregulates CETP mRNA in blood cells without affecting overall cholesterol balance in young Chinese adults (Food Sci Nutr 2022)
- HDL and CETP: a textbook chapter surveys the tunnel structure, reverse cholesterol transport role and the still-unsettled case for inhibitors versus agonists (Adv Exp Med Biol 2022)
- A systematic review of 118 randomized trials finds unsaturated fats, antioxidants, and moderate alcohol improve HDL functional traits including CETP activity (J Clin Med 2021)
- Lower plasma CETP tracks with milder depression severity, including anhedonia and guilt, in a preliminary mood-disorder proteomics study (J Psychiatr Res 2021)
- CETP concentration does not differ between peripheral artery disease patients with or without type 2 diabetes (Vasc Med 2021)
- Fetal HDL carries reduced CETP activity despite similar enzyme levels to the mother, review finds (Biomedicines 2021)
- Review names the CETP TaqIB polymorphism as one of three gene variants that heighten cardiovascular risk in heavy drinkers (Curr Neurovasc Res 2021)
- ApoC-II and apoC-III move from VLDL preferentially into larger HDL3 particles, and a CETP inhibitor does not change this transfer (Biol Chem 2021)
- Prolonged bedrest suppresses HDL cholesterol efflux capacity without affecting CETP or LCAT activity (Sci Rep 2020)
- Review questions whether HDL cholesterol is a modifiable treatment target after disappointing CETP inhibitor trials (JRSM Cardiovasc Dis 2019)
- Torcetrapib increases large HDL particles more than a novel FXR antagonist in a hamster model of dyslipidemia (Pharmacol Res Perspect 2018)
- A review of PLTP and CETP in atherogenesis weighs the mixed record of CETP inhibitors against open questions about PLTP (Adv Clin Exp Med 2018)
- Review maps CETP-mediated transfer as the indirect route of reverse cholesterol transport to the liver (Anatol J Cardiol 2017)
- A review appraises whether newer CETP inhibitors can avoid the off-target effects that undid torcetrapib (Curr Cardiol Rep 2016)
- A genome-wide meta-analysis in Hispanic populations confirms CETP as a genome-wide-significant locus for HDL cholesterol (Sci Rep 2016)
- Electron microscopy shows CETP binds HDL through hydrophobic surface interactions, not protein contacts (Sci Rep 2015)
- Atomistic simulations reveal how CETP penetrates HDL via a tryptophan anchor and phenylalanine barrier (J Lipid Res 2015)
- Torcetrapib raises HDL cholesterol in primates without touching non-HDL cholesterol, distinguishing it from an FXR antagonist tested alongside it (Life Sci 2014)
- Review surveys HDL-targeted therapies as CETP inhibitor trials split between discontinuation and ongoing phase III testing (Circ Res 2014)
- A review argues the torcetrapib setback shifted focus from HDL cholesterol quantity to HDL particle functionality (Am J Ther 2014)
- Review asks why targeting HDL for cardiovascular protection has not delivered clinical benefit (J Cardiovasc Pharmacol 2013)
- A stroke-prevention review flags CETP inhibitor trial success as a potential turning point for dyslipidemia treatment (Maturitas 2013)
- Two CETP variants are among only eight significant HDL predictors identified across 65 SNPs and 23 candidate genes (Lipids Health Dis 2013)
- CETP variant rs17231506 is one of five genes shaping sex-specific cholesterol efflux capacity independent of HDL-C (Arterioscler Thromb Vasc Biol 2013)
- Review notes CETP inhibitors raise HDL-C by 31-138 percent, but whether this lowers coronary risk remains unresolved (Circ J 2013)
- Broad review on residual cardiovascular risk after statins notes anacetrapib and evacetrapib survive where two other CETP compounds failed (Vasc Health Risk Manag 2013)
- Annual exercise-genomics review highlights physical activity modifying how CETP and two other genes affect HDL cholesterol (Med Sci Sports Exerc 2012)
- LDL apheresis transiently reduces CETP-mediated cholesteryl ester transfer and cholesterol efflux capacity in familial hypercholesterolemia (J Lipid Res 2012)
- NMR fine-mapping finds CETP among only four loci linked to bulk serum lipids, versus eight linked to lipoprotein subfractions (Hum Mol Genet 2012)
- A review questions whether CETP inhibition can reduce cardiovascular events given the complex link between CETP loss-of-function and coronary risk (Curr Cardiol Rep 2011)
- Review notes CETP transgene expression normalizes hepatic HDL cholesteryl ester delivery in humanized SR-BI knockout mice (World J Gastroenterol 2010)
- CETP Taq1B polymorphism shows no effect on HDL cholesterol or coronary artery disease risk in a Turkish angiography cohort (Genet Test Mol Biomarkers 2010)
- CETP activity stays unchanged despite severely disrupted lipoproteins in Hantaan virus renal failure (BMB Rep 2010)
- A review finds niacin remains the most potent HDL-raising therapy while CETP inhibitors stand closest to clinic despite the mortality signal seen with torcetrapib (Curr Treat Options Cardiovasc Med 2010)
- Low CETP activity and enhanced HDL2 paraoxonase found together in a patient with unusually low LDL-to-cholesterol ratio (Int J Mol Med 2010)
- A dietary lysine-to-arginine ratio trial finds no effect on CETP or LCAT activity, though it modestly shifts postprandial VLDL, triglycerides, and inflammation markers (Atherosclerosis 2010)
- CETP -629C>A polymorphism is not among the genetic determinants of coronary artery disease in Turks despite its HDL cholesterol effect (Cell Biochem Funct 2009)
- Clinician's overview names CETP inhibitors the most potent HDL-raising drugs, but torcetrapib fell to excess cardiovascular harm (Angiology 2009)
- A perspective argues the torcetrapib failure should redirect HDL drug development away from raw cholesterol concentration and toward specific antiatherosclerotic components (Ann Clin Biochem 2009)
- A review argues the torcetrapib failure highlights HDL functionality, not raw HDL cholesterol level, as the real therapeutic target (Curr Opin Investig Drugs 2008)
- Serum CETP is lowest at birth and rises sharply to peak levels in infancy, reference data from healthy Chinese children (Clin Biochem 2008)
- A review proposes injecting synthetic HDL directly as an alternative after torcetrapib, the furthest-developed HDL-raising pill, was halted for excess mortality (Nutr Metab Cardiovasc Dis 2008)
- A review attributes the excess deaths seen with torcetrapib to an off-target effect, not to CETP inhibition, while low HDL remains an important risk marker (Curr Opin Endocrinol Diabetes Obes 2008)
- A review argues the torcetrapib failure shifted laboratory focus from HDL cholesterol concentration to HDL particle heterogeneity and function (Clin Chem 2008)
- A review revisiting a 40-year-old study names the CETP, VLDL-triglyceride, and hepatic lipase cluster as drivers of atherogenic HDL and LDL remodeling (Rom J Intern Med 2008)
- Metabolic syndrome patients show hypoadiponectinemia, elevated adhesion molecules, and higher CETP-mediated cholesteryl ester-triglyceride exchange (Atherosclerosis 2008)
- Vitamin E supplementation modestly lowers HDL cholesterol in statin-treated patients without affecting CETP or CYP3A activity (Am J Health Syst Pharm 2007)
- Rosuvastatin lowered CETP activity and mass while raising HDL-C in metabolic syndrome patients (Atherosclerosis 2008)
- A review argues the torcetrapib failure highlighted the gap between HDL cholesterol levels and HDL anti-inflammatory function (J Clin Lipidol 2007)
- Review concludes the link between CETP and atherosclerosis risk depends on gene-environment interaction, unlike the direct effects of APOA1 and ABCA1 (Curr Opin Lipidol 2007)
- Torcetrapib can raise HDL cholesterol by up to 106 percent alone or combined with atorvastatin, a review of emerging HDL-raising therapies notes (Curr Drug Targets 2007)
- Mini-review places CETP-mediated cholesteryl ester transfer within the broader reverse cholesterol transport pathway (Rom J Intern Med 2007)
- Unlike hepatic lipase and LPL variants, the CETP-HDL cholesterol link is not modified by dietary fat intake in a large biracial cohort (Atherosclerosis 2007)
- A review makes the case for CETP inhibition as a novel strategy to reduce residual atherosclerotic risk beyond statin therapy (Eur Heart J 2007)
- Simvastatin lowers cholesterol in cholesterol-fed rabbits without changing CETP activity (Drug Dev Ind Pharm 2006)
- CETP TaqIB genotype link to HDL-C is stronger in alcohol drinkers than non-drinkers (Atherosclerosis 2007)
- A review of HDL-raising therapy notes that both JTT-705 and torcetrapib attenuate aortic atherosclerosis in cholesterol-fed rabbits (Pharmacol Ther 2006)
- A review outlines early evidence that CETP inhibitors JTT-705 and torcetrapib raise HDL and lower LDL cholesterol in mildly dyslipidaemic patients (Expert Opin Investig Drugs 2006)
- Review traces how statins raise HDL cholesterol partly via a secondary reduction in CETP activity (Curr Atheroscler Rep 2006)
- A review argues raising HDL with torcetrapib is a promising new approach to atherosclerosis, pending trials with hard clinical endpoints (Recent Pat Cardiovasc Drug Discov 2006)
- A review proposes that CETP is one of four enzymes that remodel spherical HDL into the lipid-poor apoA-I needed for reverse cholesterol transport (Arterioscler Thromb Vasc Biol 2006)
- SR-BI processing of HDL2 segregates apoA-I and apoA-II catabolism into distinct particles, independent of CETP, LCAT, or PLTP (J Lipid Res 2005)
- A review of four lipid transfer proteins highlights the early human results of torcetrapib as opening a new era in coronary heart disease prevention (Atherosclerosis 2005)
- Review makes the case for pharmacological CETP inhibition as a therapeutic strategy pending clinical trial confirmation (Curr Top Med Chem 2005)
- Torcetrapib 120 mg per day raises HDL cholesterol by 46 percent and lowers LDL cholesterol by 8 percent in subjects with low HDL, a review reports (Expert Opin Investig Drugs 2004)
- Review weighs CETP inhibition's physiology and animal-to-human evidence as a candidate route to raising HDL cholesterol (Curr Atheroscler Rep 2004)
- Large pharmacogenetic screen finds CETP-HDL response to pravastatin too weak to qualify, unlike the dominant HMG-CoA reductase signal (JAMA 2004)
- Review names CETP inhibitors among emerging HDL-targeted therapies for insulin resistance syndrome (Semin Vasc Med 2004)
- Postprandial chylomicrons are up to 40 times more potent than VLDL at accepting cholesterol from LDL and HDL via LCAT and CETP (J Lipid Res 2004)
- Omega-3 fatty acid concentrate selectively raises HDL2 cholesterol by 40% and paraoxonase by 10% without affecting CETP or LCAT in familial combined hyperlipidemia (Metabolism 2004)
- A review names CETP among three plasma factors that release lipid-poor apoA-I from HDL during remodeling, the key acceptor for ABCA1-mediated cholesterol efflux (Arterioscler Thromb Vasc Biol 2004)
- The effect of CETP genotype on HDL cholesterol is unaffected by physical activity level in a population-based Swiss cohort (Med Sci Sports Exerc 2003)
- A review of HDL structure names CETP among four proteins, alongside LCAT, SR-BI, and ABCA1, that remodel HDL particles in vivo (Front Biosci 2003)
- Men who respond strongly to dietary cholesterol also show higher CETP activity during high-egg feeding, suggesting boosted reverse cholesterol transport (J Nutr 2003)
- ApoA-I-free HDL-LpE particles are more than twofold more abundant in CETP-deficient subjects and efflux cholesterol as effectively as apoA-I (J Lipid Res 2003)
- Estradiol fatty-acid esters transfer from HDL to LDL via a CETP-associated process, a review finds, while their broader physiologic roles remain under study (Cardiovasc Res 2002)
- Review names CETP inhibitors among five emerging drug targets for lipid disorders beyond statins (Curr Atheroscler Rep 2002)
- A newly mapped major gene, not CETP or five other known HDL genes, controls large HDL particle levels in baboons (Atherosclerosis 2002)
- Genetic CETP deficiency nearly doubles plasma PLTP concentration by accumulating its inactive form (J Lipid Res 2002)
- Review names CETP inhibitors among four novel drug classes targeting low HDL cholesterol (Expert Opin Investig Drugs 2001)
- High-trans-fat margarine trends toward higher CETP levels while lowering cholesterol esterification rate (J Lipid Res 2001)
- Thyroid hormone excess doubles CETP activity and accelerates HDL clearance in transgenic mice (Metabolism 2001)
- A review names PLTP and CETP as joint targets of the nuclear receptors FXR and LXRalpha, central to reverse cholesterol transport (Curr Pharm Des 2001)
- Red wine, not alcohol alone, raises HDL cholesterol and cholesterol efflux capacity 7% in young men, without altering CETP (Nutr Metab Cardiovasc Dis 2000)
- Review argues the role of CETP and reverse cholesterol transport defects in diabetic atherosclerosis remains unproven, despite altered HDL composition (Diabetes Metab Res Rev 2000)
- Heat-induced loss of plasma gamma-LpE exceeds 80% but is independent of LCAT or CETP activity (J Lipid Res 1998)
- Triglyceride enrichment, not CETP alone, is what makes PLTP remodel HDL into larger and smaller particles (J Lipid Res 1998)
- A review names LCAT, hepatic lipase, and CETP as the key HDL-remodeling enzymes suppressed during cytokine-driven hyperlipidemia (Z Ernahrungswiss 1998)
- Low-HDL-cholesterol normolipidemic men show a shift from alpha1 to alpha3 HDL subpopulations, possibly via CETP-driven interconversion (Arterioscler Thromb Vasc Biol 1997)
- ApoA-IV 360His variant, not CETP or LCAT activity, explains why some people respond more to dietary fat changes (J Lipid Res 1997)
- Continuous and cyclic HRT regimens both reshape HDL subclasses in postmenopausal women without altering CETP activity (Atherosclerosis 1997)
- Swapping dietary palmitic acid for trans elaidic acid raises CETP activity and lowers HDL more in cebus monkeys (J Nutr 1997)
- A review identifies LCAT and CETP as the two key enzymes driving reverse cholesterol transport, though its antiatherogenic role remains unproven (Can J Cardiol 1996)
- A review names CETP among four enzyme mutations that reshape HDL particle size and regulate HDL cholesterol and apoA-I levels (Curr Opin Lipidol 1996)
- A multi-step synthesis from diosgenin yields two novel cholest-15-one steroids tested for CETP-inhibiting activity (Bioorg Med Chem 1995)
- Hepatic lipase, insulin, and triglycerides, not CETP or LPL activity, independently predict low HDL2b in men with NIDDM and coronary disease (J Lipid Res 1995)
- A silver-stained PCR-SSCP assay rapidly detects the intron 14 CETP-deficiency mutation without radioactivity (Clin Chem 1994)
- Alcohol-induced HDL cholesterol rise is driven by lipoprotein lipase, not CETP, hepatic lipase, or LCAT activity (Atherosclerosis 1994)
- Review weighs the shuttle versus ternary-complex models for how CETP transfers lipids and flags evidence for a pro-atherogenic role (Clin Exp Pharmacol Physiol 1994)
- A review names CETP, LCAT, and lipases as the enzymes driving HDL subclass interconversion in mature HDL formation and reverse cholesterol transport (Curr Opin Lipidol 1994)
- Horses show no significant cholesteryl ester transfer protein activity despite having VLDL, LDL, and HDL (Comp Biochem Physiol B 1993)
- A PCR-based site-directed mutagenesis method detects one CETP-deficiency homozygote and three heterozygotes among 554 Japanese subjects (Biochim Biophys Acta 1993)
- HepG2 cells secrete an unidentified factor that reshapes nascent HDL into HDL2b particles, with cholesteryl ester transfer detected but not attributable to CETP (J Lipid Res 1993)
- A review names LCAT and CETP as the joint enzymatic drivers of reverse cholesterol transport from tissues to the liver (J Am Osteopath Assoc 1992)
- A symposium report names LCAT and CETP as joint mediators of the Glomset reverse cholesterol transport hypothesis, still clinically unproven (J Lipid Res 1990)
- Cholesterol feeding boosts CETP mRNA up to 5-fold via LXRalpha in rabbits before FXR activation catches up (J Lipid Res 2003)
- The inability of rat serum to transfer dietary oxidized cholesterol to LDL/HDL points to CETP as the mediator (J Lipid Res 2003)
- A review by Barter and Rye finds continuing conflict in the evidence on whether cholesteryl ester transfer protein is atherogenic or anti-atherogenic (Curr Opin Lipidol 2001)
- A methods chapter frames CETP, also known as lipid transfer protein I, as the enzyme linking triglyceride-rich and cholesterol-rich lipoprotein metabolism (Methods Mol Med 2001)
- An apoA-I promoter variant does not affect HDL cholesterol regardless of CETP deficiency status in Japanese subjects (Hum Genet 1995)